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ABSTRACT OF DISSERTATION 
VIRAL FUSION PROTEIN TM-TM INTERACTIONS: MODULATORS OF PROTEIN 
FUNCTION AND POTENTIAL ANTIVIRAL TARGETS 
Enveloped viruses, such as HIV, influenza, and Ebola, utilize surface 
glycoproteins to bind and fuse with a target cell membrane. This fusion event is 
necessary for release of viral genomic material so the virus can ultimately reproduce and 
spread. The recently emerged Hendra virus (HeV) is a negative-sense, single-stranded 
RNA paramyxovirus that presents a considerable threat to human health as there are 
currently no human vaccines or antivirals available. The HeV utilizes two surface 
glycoproteins, the fusion protein (F) and the attachment protein (G), to drive membrane 
fusion. Through this process, the F protein undergoes an irreversible conformational 
change, transitioning from a meta-stable pre-fusion conformation to a more 
thermodynamically stable post-fusion structure. Understanding the elements which 
control stability of the pre-fusion state and triggering to the post-fusion conformation is 
important for understanding F protein function. Studies that replace or mutate the TM 
domain of the F protein of several viruses implicated the TM domain in the fusion 
process, but the structural and molecular details in fusion remain unclear. Previously, 
analytical ultracentrifugation was used to demonstrate that isolated TM domains of HeV 
F protein associate in a monomer-trimer equilibrium. To determine factors driving this 
association, we analyzed the sequence of several paramyxovirus F protein TM domains 
and found a heptad repeat of β-branched residues. Analysis of the HeV F TM domain 
specifically revealed a heptad repeat leucine-isoleucine zipper motif (LIZ). Replacement 
of the LIZ with alanine resulted in dramatically reduced TM-TM association. Mutation of 
the LIZ in the whole protein resulted in decreased protein expression and pre-fusion 
conformation. To further understand the role of the TM domain, the TM domain was 
targeted as a potential modulator of F protein stability and function. Exogenous HeV F 
TM constructs were co-expressed with the full length F protein in Vero cells to analyze 
the effects on protein expression. Co-expression of the exogenous HeV F TM constructs 
dramatically reduced the expression of HeV F.  However, the co-expression of exogenous 
HeV F TM constructs with a different paramyxovirus F protein, PIV5 F, did not strongly 
affect PIV5 F expression levels, suggesting that the interaction of the exogenous TM 
constructs is specific. Fusion assays revealed that HeV F TM constructs dramatically 
reduced HeV F, but not PIV5 F fusion activity. We hypothesize that the short exogenous 
HeV TM constructs associate with the TM domain from full-length HeV F, resulting in 
pre-mature triggering or protein misfolding. The work presented here demonstrates that 
specific elements in the TM domain contribute to TM association and pre-fusion protein 
stability. Furthermore, targeting these interactions may be a viable approach for antiviral 
development against this important pathogen. 
KEYWORDS: Membrane Fusion, Viral Fusion Protein, Paramyxovirus, 
Transmembrane Domain 
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Chapter 1: INTRODUCTION 
MEMBRANE PROTEINS 
A search of the protein data bank (PDB) for membrane proteins results in a hit 
number that represents less than 3% of total reported structures. This is an incredible 
short-coming in the field considering that estimates suggest 20-30% of all open reading 
frames encode for membrane proteins. More importantly, almost 50% of drugs currently 
target membrane proteins (1). This large gap in the field is primarily the result of the 
difficulty encountered when studying hydrophobic domains of membrane proteins, and 
impacts research areas such as cell signaling and viral infection. Enveloped viruses, 
including members of the paramyxovirus family, such as measles virus, mumps virus, 
and the zoonotic Hendra virus (HeV), utilize surface membrane proteins to promote the 
vital steps of attachment and membrane fusion. Membrane fusion of the viral envelope 
and target cell membrane is a critical early step in infection. Though there have been 
many advances in the field, the details of the mechanism that the viral envelope proteins 
utilize to drive fusion remains to be clearly understood.  
PARAMYXOVIRUSES 
The Paramyxoviridae family is a family of enveloped, negative-strand RNA 
viruses composed of several human pathogens, such as measles virus, parainfluenza virus 
(1, 2, 3, 4a and 4b), and mumps virus (2). Within the paramyxoviridae family, there are 
five genera: ferlavirus, Henipavirus, morbillivirus, respirovirus, and rubulavirus. Viruses 
of the paramyxoviridae family are spread through the respiratory route with many being 
highly contagious. Members of this family include mumps, human parainfluenza viruses, 
and measles, which caused over 134,000 deaths in 2015 and remains one of the leading 
causes of death for young children. Paramyxoviruses contain a 15 to 19 kB non-
segmented genome that produces six to ten gene products, which are important for virus 
replication and entry. The proteins encoded include the large polymerase (L), 
nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), fusion protein (F) and 
attachment protein (HN/H/G) (Fig 1.1). The L protein is the largest viral protein and is 
responsible for initiation, elongation, and termination of mRNA transcription and genome 
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replication. The N protein encapsulates the viral genome. The P protein is necessary for 
genome replication and makes up the replication complex with N and L. Virion structure 
is maintained by the M protein, which is found on the inner surface of the viral envelope 
(3). Entry of paramyxoviruses is mediated by two glycoproteins studding the surface of 
the virion. The attachment protein (HN/H/G) is generally important for the role of 
adsorption to the target cell by binding to a cellular receptor protein. The fusion protein 
(F) is necessary for fusion of the viral membrane with the target cell membrane (4). The 
fusion process requires energy to merge the two membranes, which is thought to be 
provided by the large conformational change that the fusion protein undergoes upon some 
triggering event. The fusion protein is initially found in a meta-stable conformation and, 
upon triggering, refolds to the lower energy post-fusion conformation, which produces 
energy that aids in membrane fusion (5). Triggering of the fusion protein to undergo the 
conformational changes needed to form the post-fusion structures is not fully understood, 
with some fusion proteins triggering under acidic conditions, while others are thought to 
trigger as a result of an interaction with the attachment protein. Ultimately, the fusion of 
the two membranes results in release of the viral genome within the target cell, where the 
genome can undergo replication and transcription for further virus amplification.  
The newest human pathogens in this family include the closely related Hendra 
and Nipah virus, two highly pathogenic, zoonotic viruses. Because of their genetic 
similarity, high virulence, and broad host range, Hendra and Nipah were classified into 
their own genus, Henipavirus (6). The Hendra virus was first identified in 1994 when an 
outbreak in Queensland, Australia resulted in the death of several horses and one trainer. 
The infection presented as an acute respiratory syndrome and resulted in a second human 
fatality a year later resulting from viral meningoencephalitis. Transmission of Hendra 
virus has been reported from bat to horse, and horse to human, with a total of 55 
occasions of Hendra virus detected in Eastern Australia as of 2015 (7, 8). These incidents 
resulted in the death or euthanasia of 97 horses, two Hendra virus antibody positive and 
euthanized dogs, and four fatalities out of seven human cases. The closely related Nipah 
virus was identified a few years after Hendra virus in 1998 when there was a large 
encephalitis outbreak in pig farmers in Malaysia (9). The newly discovered Nipah virus 
was found to cross-react with antibodies against Hendra virus. Nipah has been found to 
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transmit from bat to pig, pig to human, bat to human, and human to human directly. The 
most recent incidence of human infection occurred in 2015 resulting in nine human 
fatalities (7). The high mortality rates, suspected human to human transmission and lack 
of currently available human vaccines for Hendra or Nipah virus resulted in classification 
of these viruses as biosafety level 4 (BSL-4) pathogens (10).  
Identification of these zoonotic viruses reinforces the premise that newly 
emergent viruses have the potential to dramatically affect public health. The WHO 
identified Nipah virus as one of the top emergent pathogens, alongside viruses such as 
Ebola, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome 
(MERS) (11). Hendra virus infection generally presents as systemic infection, especially 
resulting in neurological and/or respiratory tropism with the potential for encephalitis to 
relapse or become chronic in nature. Henipavirus has a broad geographical distribution in 
humans and animals throughout Malaysia, Bangladesh, Singapore, and Australia (12). 
The natural host is likely the Pteropus bat, also known as the flying fox. The large habitat 
range and more than 60 species of Pteropus bat indicate the potential for disastrous 
Henipavirus outbreaks (13, 14). Together, the characteristics of the host and the 
Henipavirus call for the development of a human vaccine, as there is none currently 
available.  
 
SURFACE GLYCOPROTEINS 
Paramyxoviruses are enveloped viruses with two major glycoproteins studding 
the surface of the virus. These proteins are important for the initial interaction of the virus 
with its target cell; they mediate receptor binding and membrane fusion. There is an 
additional third glycoprotein, the small hydrophobic protein (SH) that is expressed by 
members of the Rubulavirus genus, such as PIV5. The attachment protein is designated 
as hemagglutinin (H), hemagglutinin neuraminidase (HN), or glycoprotein (G) depending 
on the virus. The fusion protein (F) drives membrane fusion via dramatic conformational 
changes (15-17). Together the attachment and fusion protein are ultimately responsible 
for viral entry into the host cell.  
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Paramyxoviridae attachment protein 
 Paramyxovirus attachment proteins are structurally similar and all mediate 
attachment to the target cell, but can vary in specific function. The attachment proteins 
are classified by their ability to bind sialic acid as a receptor and the ability to cleave 
sialic acid. The attachment protein HN (hemagglutinin-neuraminidase) is able to bind and 
cleave sialic acid. Viruses of the Avulavirus, Respirovirus, and Rubulavirus genera utilize 
HN proteins as their attachment protein. The attachment protein H (hemagglutinin) is 
only able to bind sialic acid, lacking neuraminidase activity. Canine distemper virus, a 
Morbillivirus, expresses the H attachment protein (18-23). Interestingly, measles virus 
also utilizes the H attachment protein, how it uses a protein receptor, CD46 (24). Lastly, 
the attachment protein G, utilized by the Henipaviruses, maintains neither sialic acid 
binding nor neuraminidase activity, but is able to bind protein receptors.  Specifically, the 
Hendra virus G protein has been found to bind to the cellular proteins, ephrin B2 and B3 
(25-27). Though the mechanism of attachment varies, the attachment proteins of the 
paramyxovirus family are structurally similar; they are type II transmembrane proteins 
composed of an N-terminal cytoplasmic tail, a single-pass transmembrane domain, a four 
helix bundle stalk, and a globular head. The attachment glycoproteins are found as a 
dimer of dimers, resulting in a di-sulfide linked tetramer.  Additionally, it has been found 
that most Paramyxoviridae require their homotypic attachment protein for membrane 
fusion (2, 28-31). The closely related Hendra and Nipah viruses can utilize either 
Henipavirus attachment protein (32-34). This necessity is likely the result of the 
attachment protein’s proposed dual functionality. The attachment protein is required for 
attachment to the target cell, and it has also been proposed that it is involved in fusion 
protein triggering. Though the mechanistic details are not clear, it is evident that the 
fusion protein is unable to drive membrane fusion without expression of the 
corresponding attachment protein in vitro.  
 
Paramyxoviridae fusion protein 
 Paramyxovirus F proteins are synthesized as non-fusogenic homo-trimers, 
referred to as F0. This type-I integral membrane protein must undergo proteolytic 
processing to its active form as a disulfide linked heterodimer, F1+F2. The paramyxovirus 
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F protein has a domain structure, consisting of a hydrophobic fusion peptide (FP), two 
heptad repeat regions (HRA and HRB), a single-pass transmembrane domain (TM), and a 
C-terminal cytoplasmic tail (CT) (Fig 1.2A) (18, 35). The F protein is inserted into the 
endoplasmic reticulum (ER), where it is co-translationally folded into its tertiary trimeric 
structure (Fig 1.2B). Proper folding and glycosylation is necessary for proper F protein 
function. N-linked glycosylation sites can be found within the F protein ectodomain, 
though the specific sites vary among viruses in the Paramyxoviridae family.  The Hendra 
virus F protein contains six sites (N-X-S/T) for N-linked glycosylation, with three in the 
F2 subunit and the other three upstream of the TM domain. Four sites (N67, N99, N414 
and N 464) were found to be important for F protein folding and fusion activity (36).  
 Cleavage of the F protein from its inactive state, F0, to the active disulfide linked 
heterodimer is important for the pathogenicity of the virus. Upon cleavage, a new N-
terminus is exposed in the F1 subunit, the fusion peptide, which is a highly hydrophobic 
domain that is responsible for insertion into the target membrane (37). Though cleavage 
is necessary for all paramyxovirus F proteins, the protease necessary for cleavage may 
vary between viruses. For most F proteins, the cleavage event takes place as the F protein 
traffics through the trans-Golgi network and is mediated by furin, a ubiquitous subtilisin-
like cellular protease (38, 39). Furin recognizes the sequence R-X-K/R-R and has been 
found to be responsible for the cleavage of several paramyxovirus F proteins, including 
PIV5 and mumps virus (39). Hendra and Nipah virus do not contain the R-X-K/R-R 
sequence for furin cleavage, but instead are cleaved by cathepsin L, an 
endosomal/lysosomal cysteine protease that recognizes a single basic residue in the N-
terminal sequences VGDVK109 and VGDVR109, respectively (40, 41). Since cleavage 
occurs in the endosome, the Nipah virus contains a tyrosine-based endocytosis signal 
(Y525RSL) in the C-tail that is essential for efficient cleavage (42). Currently, the known 
paramyxoviruses only require a single cleavage event for activation. Some viruses, 
including Sendai virus and human parainfluenza virus 1 (hPIV1) utilize tissue-specific 
extracellular proteases (38, 43). Respiratory syncytial virus (RSV), a pneumovirus, 
requires two cleavage events for fusion (44). The cleavage step is essential for not only 
the function of the fusion protein, but also for pathogenicity and virulence. 
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VIRAL MEMBRANE FUSION 
 Enveloped viruses must overcome a challenging barrier in order to mediate entry 
into its target cell. The envelope of the viral particle must fuse with the cell membrane to 
facilitate the release of viral components and ultimately function intracellularly. Fusion of 
two membranes is thermodynamically favorable; thus a kinetic barrier must be overcome. 
As the membranes come into close contact, the repulsive hydration force of the polar 
head groups must be overcome (Fig1.3A). The energy required to drive membrane fusion 
is thought to be provided by the conformational change of the fusion protein. The most 
widely accepted model of viral membrane fusion proposes that fusion occurs through a 
hemi-fusion state, where only the outer leaflet of the bilayers is merged. Upon 
completion of fusion protein refolding, the membranes fuse completely, resulting in the 
formation of a fusion pore (Fig 1.3B). This model is supported by studies in which hemi-
fusion was observed with wild-type fusion proteins by slowing the fusion reaction with 
inhibitors, or decreasing fusion protein density on the surface (5, 45, 46). Although there 
is little sequence homology, an assorted group of viral fusion proteins including HIV env, 
influenza HA, and paramyxovirus F proteins drive membrane fusion through 
conformational changes in the fusion protein. These diverse fusion proteins can be 
divided into three classes to more specifically describe their mechanism of fusion, though 
there may be some viral fusion proteins that do not fit into any of these classes. While the 
fusion proteins are fairly diverse, they ultimately must drive membrane fusion for entry 
into the target cell.     
 
Class I fusion proteins 
 Several important viral families utilize class I fusion proteins to mediate 
membrane fusion; these viral fusion proteins include Hendra virus F, HIV env, and 
influenza HA. Crystallography, NMR, and cryo-electron microscopy have provided great 
insights into the structure of the pre- and post-fusion conformations of several fusion 
proteins, including parainfluenza virus 5 (PIV5) F, Hendra virus F, and HIV env (47-50). 
Class I fusion proteins are present on the viral surface as trimers in a meta-stable pre-
fusion conformation. Some class I fusion proteins require proteolytic cleavage to prime 
the fusion protein for membrane fusion. Influenza hemagglutinin (HA), one of the most 
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well studied class I fusion proteins, requires cleavage to expose the fusion peptide 
domain. Upon some triggering event, a series of dramatic conformational changes result 
in the formation of a more stable post fusion conformation, in a process that is essentially 
irreversible. The energy released during this conformational rearrangement of the protein 
is thought to drive the fusion process. The triggering event can vary for different viral 
fusion proteins. For example, influenza HA is triggered upon exposure to low pH, 
whereas the HIV env protein initiates its conformational change upon receptor binding 
(51, 52). Class I fusion proteins exhibit a characteristic post-fusion conformation in 
which the protein is found as a trimer of α-helical hairpins with a central coiled-coil.  
Paramyxovirus fusion proteins are categorized as class I fusogens and exhibit 
many of the characteristic features of class I fusion. The fusion protein is initially found 
in a meta-stable pre-fusion conformation. This conformation has a globular head, in 
which the highly hydrophobic fusion peptide is buried, and a coiled-coil stalk domain 
comprised of the HRB domain that is anchored in the viral membrane by a hydrophobic 
transmembrane domain. Proteolytic cleavage is required for activation of paramyxovirus 
fusion proteins, though the enzymes used for cleavage vary. Hendra F protein is cleaved 
by cathepsin L, whereas Newcastle disease virus fusion protein is cleaved by furin (41, 
53-55). Upon triggering, the fusion peptide is released for insertion into the target cell 
membrane, while the HRA and HRB domains fold into a stable six-helix bundle. The 
triggering event is thought to be initiated by receptor binding of the attachment protein, 
though there are several proposed models, which will be discussed in detail later. The 
formation of the six-helix bundle is thought to provide some of the energy needed for 
merging the two lipid bilayers.  
 Key conserved residues have been implicated in the fusion process for several 
paramyxovirus fusion proteins. Previously, alignment of a set of paramyxovirus F 
proteins identified a conserved region between the two heptad repeat regions in the F1 
segment. Residues in this conserved region were mutated in the Hendra and PIV5 F 
protein, resulting in proteins that were defective in proteolytic processing, trafficking, and 
oligomerization of the F protein (56). Fusion activation of PIV5 F was found to be 
enhanced when co-expressed with a headless attachment protein, implicating interaction 
with the attachment protein stalk domain in triggering (57). Additional studies with PIV5 
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F found that multiple hydrophobic residues toward the lower part of the pre-fusion F 
globular head were important for F-HN interaction (58). The measles virus F protein was 
also shown to receive a triggering signal at the base of its F protein head. Six residues 
were found to be important for fusion with four of the identified residues positioned near 
the base of the F protein head (59). NiV F protein was shown to prematurely trigger when 
co-expressed with a headless form of the G protein, again suggesting the importance of 
fusion protein-attachment protein interactions in triggering. It has been proposed that the 
G protein head conceals the residues in the stalk domain that are important for triggering 
until receptor binding has occurred (60). In addition, residues within the C-tail of the NiV 
F protein were shown to be important for membrane fusion. A KKR motif was found to 
be involved in inside-out signaling; truncation of the C-tail reduced cell-cell fusion and 
mutation of the KKR motif altered fusion activity (61). Despite these advancements, 
significant questions remain regarding intermediates and maintenance of the pre-fusion 
conformation.  
 
Class II fusion proteins 
 The dimer-to-trimer transition is the hallmark characteristic of class II viral 
membrane fusion. Despite this difference, the overall mechanisms of membrane fusion 
follow similar structural themes as class I. Several important pathogens, including 
Dengue, Semliki Forest, and West Nile virus, express class II fusion proteins. The fusion 
proteins in this class are initially folded as hetero-dimers that are maintained in the pre-
fusion conformation by chaperone proteins (62-67). Unlike the largely alpha-helical class 
I fusion proteins, class II fusion proteins are primarily composed of β-sheet. After 
receptor binding and triggering by low pH, the fusion protein must dissociate, allowing 
insertion of the fusion peptide into the target cell membrane. Upon insertion, the fusion 
protein oligomerizes as a homo-trimer, folds back on itself and mediates hemi-fusion, 
ultimately producing a viral pore via fusion. In the post-fusion conformation, the fusion 
protein differs from the class I fusion protein in that the final conformation is a trimer of 
hairpins, instead of the six helix bundle found in class I proteins (5). Regardless of this 
difference, it is thought that the transition to the hairpin structure is able to drive 
membrane fusion.  
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Class III fusion proteins 
 Class III fusion proteins are utilized by several viruses, including Epstein-Barr 
virus, herpes simplex virus, and vesicular stomatitis virus (VSV) (68, 69). The most well 
studied class III fusion protein is the VSV G glycoprotein. Although both class I and II 
fusion proteins undergo irreversible conformational changes, class III fusion proteins are 
unique in that some members can reverse the conformational change, such as VSV-G, 
depending on pH conditions. This distinctive characteristic is possible because the fusion 
protein does not require priming, such as proteolytic cleavage as seen with class I fusion 
proteins. In the pre-fusion conformation, like class I members, the fusion protein is a mix 
of α-helical and β-sheet secondary structure, and is co-translationally folded as a trimer. 
Like members of class II, the hydrophobic fusion loops are located at the tip of the 
ectodomain and come into close proximity with the target membrane upon 
conformational changes in the ectodomain upon receptor binding and exposure to a low 
pH environment. The post-fusion conformation of VSV G is trimeric with the TM 
domain and FP on the same side of the new structure of the protein (70, 71). Ultimately, 
the post-fusion conformation can be described as a trimer of hairpins, similar to class II 
fusion proteins. The theme that can be applied to all three classes seems to be a 
requirement for protein oligomerization and conformational change upon specific 
triggering conditions.  
 
TRIGGERING AND STABILITY OF THE PRE-FUSION F CONFORMATION  
 As described for class I fusion proteins, paramyxovirus F proteins require a 
triggering event to undergo conformational changes and drive membrane fusion. The F 
protein is initially found in a meta-stable conformation, with an energy barrier between 
the pre-fusion conformation and the post-fusion. The triggering event destabilizes the 
pre-fusion conformation so the F protein can refold into the low energy post-fusion 
structure. Since the post-fusion conformation is no longer able to drive membrane fusion 
and the conformational change is considered essentially irreversible, it is important for 
the triggering process to be carefully regulated, spatially and temporally. Three types of 
fusion triggers have been described for viral fusion proteins: exposure to low pH, 
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receptor binding, and a combination of receptor binding followed by exposure to a low 
pH environment. Viruses that enter the cell via endocytosis, such as orthomyxoviruses, 
utilize low pH to drive the F protein triggering event. Receptor binding as a triggering 
event can occur via different mechanisms. The viral fusion protein may directly bind a 
receptor, an additional viral glycoprotein may be responsible for interacting with a 
receptor, and, in the case of HIV, the fusion protein can require multiple receptors.  
Members of the paramyxo-, retro-, and herpesvirus families employ receptor binding for 
triggering. Avian retroviruses are unique in that they utilize a two-step fusion activation 
mechanism that requires receptor binding followed by exposure to a low pH environment 
(72-77).  
 Paramyxoviruses differ from other class I fusion proteins, which have F proteins 
that are capable of binding the target cell receptor and driving membrane fusion. 
Members of the paramyxovirus family require two surface glycoproteins to perform these 
functions: the attachment and fusion protein. Generally, it is thought that the two 
glycoproteins interact and that the F protein is triggered as a result of some 
conformational change that occurs when the attachment protein binds its receptor. The 
details of this mechanism of activation are still unclear, though there are several models 
proposed. The first model, the sliding model, hypothesizes that the attachment protein 
head slides from a planar configuration to a staggered structure (Fig 1.4A). The change in 
conformation then results in dissociation from the F protein, allowing triggering to occur. 
The stalk-exposure model suggests that the attachment protein undergoes a 
conformational change upon receptor binding that allows the F protein to interact with 
the newly exposed attachment protein stalk (Fig 1.4B). Experiments utilizing headless 
attachment proteins of PIV5 or Measles virus to trigger the F protein support this model 
(57, 59, 78). However, there are several viruses that exhibit F-attachment protein 
interactions before the receptor binding event. A third model, the safety-catch model, 
suggests that the attachment protein is found in a heads down conformation to prevent F 
protein triggering, essentially locking the F protein (Fig 1.4C) (75). Upon receptor 
binding, the head domain of the attachment protein changes conformation which frees the 
F protein for triggering. The Nipah virus has been proposed to use yet another model, the 
bi-dentate model of triggering (79). This model suggests that the F protein interacts with 
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the attachment protein head until receptor binding, at which point the F protein associates 
with the stalk of the attachment protein. Nipah virus F and its attachment protein, G, have 
been shown to interact before receptor binding and the attachment protein has been 
shown to undergo conformational changes in the head and stalk domain after receptor 
binding, supporting the bi-dentate model (Fig 1.4D). There are some redundancies in 
these models of triggering, and more than one may appropriately describe the triggering 
mechanism for one virus, but not another. From these proposed models, it becomes clear 
that the interface at which the F and attachment protein interact is important for the F 
protein triggering process (80).  
  In addition to these protein-protein interactions, there are several regions of 
paramyxovirus F proteins that have been implicated in triggering. Most integral 
membrane proteins in the exocytic pathway are modified by oligosaccharides, such as N-
linked glycans. Previous studies have shown that N-linked glycans are important for 
proper protein folding, protein stability, and maintenance of specific conformations. Not 
surprisingly, many viral F proteins are modified by oligosaccharides, especially N-linked 
glycans. The Influenza virus HA protein contains two conserved glycosylation sites that 
are necessary for stabilizing the HA trimer (81, 82). Mutation of these glycosylation sites 
resulted in reduced cleavage, and therefore fusion activity, of the HA protein (82). The 
fusion peptide domain is highly conserved across class I viral fusion proteins and, as 
expected, is important for F protein function. There are often conserved glycine residues 
within the FP domain that are thought to be important for membrane perturbation. 
Interestingly, mutation of conserved glycine residues in the PIV5 F protein resulted in a 
hyper-fusogenic protein that could trigger even in the absence of its homotypic 
attachment protein (83). These results implicate the FP and these specific residues in the 
triggering process of the F protein. Additional regions of conservation, the heptad repeat 
domains A and B, have also been implicated in the triggering process. The Sendai virus 
has previously been targeted by peptides designed based on the HRB domain to inhibit 
membrane fusion by binding to the HRA domain in a pre-hairpin intermediate, ultimately 
preventing formation of the coiled-coil structure in the post-fusion conformation. 
Mutation of residues in the heptad repeat of the HRA domain of Sendai virus modulated 
the activity of the F protein, with some mutations resulting in hyper-fusogenic proteins 
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(84). The mutations that resulted in a hyper-fusogenic protein were hypothesized to 
enable the F protein to trigger more readily than the wild-type protein. On the other hand, 
stabilizing the pre-fusion conformation can also prevent fusion activity.  
 
MODULATING THE F PROTEIN VIA THE TRANSMEMBRANE DOMAIN 
 Though regions within the soluble ectodomain have been shown to be important 
in stability and function of the F protein, the hydrophobic anchor of class I viral F 
proteins, the transmembrane domain, has also been implicated in the fusion process. The 
transmembrane domain is essential for anchoring the protein to the viral membrane, but 
studies regarding additional roles of this domain have been limited due to the difficulty in 
working with such hydrophobic domains. Cellular proteins, such as receptor tyrosine 
kinases, have been shown to utilize their transmembrane domains for signaling. 
Neuropilin-1, a receptor tyrosine kinase that is involved in vascularization, requires a 
GxxxG motif within its transmembrane domain to promote dimerization for downstream 
signaling (85).  To determine its role in the fusion protein function, the TM domain of 
influenza virus HA was replaced with the lipid anchor, glycosylphosphatidylinositol 
(GPI), and analyzed for protein folding and function. The GPI-anchored HA protein was 
able to form stable trimers, but exhibited additional oligosaccharide modifications that 
altered the ability of GPI-HA to bind to a target cell (86). An additional study with GPI-
HA that was synthesized under conditions that resulted in glycosylation similar to that of 
the wild-type protein demonstrated that the lipid-anchored F protein was only able to 
promote hemi-fusion, not full fusion, suggesting that the TM domain is more than an 
anchor (87). A similar study was performed with the fusion protein (G) of vesicular 
stomatitis virus (VSV), in which replacement of the TM domain with GPI resulted in a 
non-fusogenic fusion protein (88). The TM domain of VSV G was suggested to be 
important for initial pore formation and content mixing, as  TM peptide of the G protein 
was able to drive vesicle fusion (89). The TM domain was thought to disrupt the 
membrane by inducing positive lipid curvature, aiding in membrane fusion.  
 Class I fusion proteins are ultimately folded as a trimer in a meta-stable 
conformation. The spring loaded conformational change must be spatially and temporally 
regulated. The cleavage activation step is one means of regulation. The TM domain has 
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been proposed as an additional region of pre-fusion maintenance. The F protein of 
Newcastle disease virus (NDV) was mutated by replacing with the TM domain of Sendai 
virus (SeV), measles virus (MV), or VSV to test for sequence specificity of the TM 
domain. The TM domain of SeV and MV resulted in a protein that was expressed and 
trafficked appropriately, however membrane fusion was defective (90). Conformation 
sensitive antibodies were used to determine that the TM domain replacement resulted in 
conformational changes in the ectodomain, implicating the TM domain in maintenance of 
the pre-fusion conformation. Since the first pre-fusion crystal structure of influenza HA 
was determined in 1981, there have only been eight unique pre-fusion structures 
determined. These include fusion proteins from different viral families, such as VSV G 
(rhabdovirus), HIV env (retrovirus), and HeV F (paramyxovirus). Structural data has 
been difficult to obtain for the pre-fusion conformation, as most often the protein triggers 
during sample preparation. Most of the structures reported to date have been modified to 
remove the transmembrane domain and C-tail, and replace them with a trimeric coiled 
coil segment, such as GCNt or foldon (the natural trimerization domain of T4 fibritin). 
Though it is evident that the TM domain of the fusion protein is important for the overall 
function of the protein, the mechanism by which the TM functions in fusion remains 
unclear.  
 Previous work from our research group by Clint Smith and Stacy Smith have 
demonstrated that the TM domain of HeV associates in a monomer-trimer equilibrium in 
isolation as determined by analytical ultracentrifugation, and that alteration of the length 
or sequence of the TM domain results in changes in protein expression and activity. 
Given these data in combination with requirement of a trimeric tag for pre-fusion protein 
crystallization, I hypothesized that the TM domain of the Hendra F protein was important 
for pre-fusion protein stability. Andreea Popa previously identified a leucine/isoleucine 
zipper (LIZ) that continued in frame from the HRB domain into the TM domain of 
Hendra F. I utilized sedimentation equilibrium AUC to determine that the LIZ was 
important for TM-TM association, as mutation of this motif resulted in a shift in 
equilibrium toward a larger monomeric population. Though mutation of the LIZ resulted 
in reduced expression in the full length F protein, I utilized a thermal triggering assay to 
demonstrate that reduced TM-TM association resulted in a protein that triggers more 
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readily than the wild type protein. Additionally, sedimentation equilibrium AUC was 
used to analyze the oligomeric state of four additional fusion protein TM domains, 
including Ebola GP, SARS CoV S, Rabies GP, and Influenza HA, representing four 
additional viral families and class I and III viral fusion proteins. The TM domains 
exhibited monomer-trimer or monomer-trimer-hexamer equilibrium. The ability of TM 
domains of these fusion proteins to oligomerize may suggest that TM-TM association is 
important for pre-fusion stability of the glycoprotein, as well. Further studies would be 
necessary to determine whether the TM domain of these proteins does contribute to pre-
fusion protein stability. Ultimately, these data provide a strong argument for the 
importance of TM-TM association in fusion protein function, specifically maintenance of 
the pre-fusion conformation.  
 
TARGETING THE F PROTEIN TM DOMAIN TO INHIBIT MEMBRANE FUSION 
 Functional data described here implicate the TM domain in membrane fusion, as 
alteration in various systems results in changes in fusion activity. The role the TM 
domain plays in the fusion protein function implicates the domain as a potential 
druggable target. With our data that demonstrate TM-TM association, I hypothesized that 
disruption of TM-TM interactions could prevent fusion by either prematurely triggering 
the fusion protein, or causing the protein to misfold. Previously, a study with Epstein-
Barr virus latent membrane protein 1 (LMP1) demonstrated that small molecule 
inhibitors could be used to target TM-TM interactions and prevent signaling (91). This 
concept can be applied beyond targeting viruses, as well. A study with the receptor 
tyrosine kinase, ErbB2/Neu, found that TM peptide mimics could prevent downstream 
signaling. The authors hypothesized that the TM peptide prevented ErbB2/Neu TM 
oligomerization, which is necessary for signaling (92).  To determine whether the TM 
domain of the Hendra F protein was targetable, I designed homologous TM constructs for 
co-expression with the F protein in cell culture. I found that the presence of the 
exogenous TM protein resulted in a dramatic reduction in expression and fusion activity. 
Additionally, TM peptides were utilized to determine whether viral infection could be 
inhibited. PIV5-GFP virus treated with PIV5 F TM peptide exhibited a reduction in 
infected cells, while HMPV treated with the same peptide maintained infection. Thus, 
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this proof of concept experiment suggests that the TM domain is a potential target, and 
the interaction of exogenous TM is protein specific.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
 
 
Figure 1.1. Schematic of paramyxovirus virion. The negative sense single stranded 
RNA genome (black line) is encapsulated by the nucleocapsid protein (purple). The 
phosphoprotein (light blue) and large polymerase (navy blue) are also found associated 
with the coated RNA genome. The matrix protein is found under the lipid bilayer and 
helps to provide structure to the virion. Two surface glycoproteins stud the lipid 
envelope, the attachment protein (peach) and the fusion protein (green).  
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Figure 1.2. Hendra F protein processing. A. The Hendra virus fusion protein (F) has a 
domain structure consisting of the highly hydrophobic fusion peptide (FP), two heptad 
repeat domains (HRA and HRB), a large ectodomain, a transmembrane domain (TM) and 
a C-tail domain (CT). B. F is synthesized as an inactive protein (F0) that requires 
cleavage by cathepsin L to a disulfide linked heterodimer (F1+F2). Cleavage occurs after 
the protein is trafficked to the plasma membrane and endocytosed. Once cleaved, the F is 
trafficked back to the plasma membrane.  
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Figure 1.3. Membrane fusion. A. Membrane fusion of two lipid bilayers with the 
intermediates depicted. B. A proposed model for fusion protein mediated membrane 
fusion that results in the fusion protein in a six helix bundle conformatin.  
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Figure 1.4. Proposed mechanisms of paramyxovirus fusion protein triggering. 
Attachment protein (left, navy blue stalk and grey head) and fusion protein (right).  
Different head group conformational changes and interactions between the attachment 
protein are shown as possible mechanisms for fusion protein triggering. The light blue 
circles on the attachment protein stalk indicate a conformational change. The yellow star 
indicates the fusion protein is active.  
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Chapter 2: MATERIALS AND METHODS 
 
CELL LINES AND CULTURE 
Vero cells, kindly provided by Robert Lamb, HHMI/Northwestern University and 293T 
cells, generously provided by Judith White, University of Virginia, were maintained in 
Dulbecco’s modified Eagle’s media (DMEM; Invitrogen) supplemented with 10% fetal 
bovine serum (FBS).  
 
PLASMIDS AND ANTIBODIES 
Plasmids containing Hendra F or G in the pGEM vector were generously provided by Dr. 
Lin-Fa Wang (Australian Animal Health Laboratory). Plasmids containing PIV5 F or HN 
were kindly provided by Robert Lamb, HHMI/Northwestern University. All Hendra F 
mutants were made in pGEM using the QuikChange site-directed mutagenesis kit 
(Stratagene) and subcloned into the eukaryotic expression vector pCAGGS (93). The 
short (D482-T546), long (Q478-T546) and HRB (I460-T546) linker TM genes were 
ordered from GenScript. The cut sites ClaI and XhoI were added to the N- and C-
terminus, respectively, for sub-cloning into the pCAGGS expression vector. 
Staphylococcal nuclease fused to the TM domain of glycophorin A (GpA) in the pET-11a 
expression vector was generously provided by Dr. Karen Fleming (The Johns Hopkins 
University) (94). Analytical ultracentrifugation constructs containing either the wild-type 
or mutant Hendra F TM domain were cloned into pET11a using XmaI and XhoI sites at 
the 5’ and 3’ ends, respectively. Genes for the Ebola GP TM (residues 651-672), SARS 
CoV S TM (residues 1193-1227), Rabies GP TM (residues 429-461), and Influenza HA 
TM (residues 511-536) were ordered from GenScript and cloned into pET11a, as 
described for Hendra F TM. Constructs were sequenced to confirm sequence integrity. 
Anti-peptide antibodies to residues 527-539 of the Hendra F cytoplasmic tail were used 
to pull down F. PIV5 F immunoprecipitation was performed with a rabbit anti-peptide 
antibody to the PIV5 F C-tail residues 516-529. For immunoprecipitation, mAb 5G7 was 
used to detect the HeV F protein and the pre-fusion conformation of HeV F was detected 
using mAb 5B3, both antibodies were generously provided by Dr. Christopher Broder 
(Uniformed Services University of the Health Sciences).  
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TRANSIENT TRANSFECTION  
All mutant or wild-type Hendra F, Hendra G, PIV5 F, or PIV5 HN constructs were 
transiently expressed using the mammalian expression vector pCAGGS allowing for high 
levels of protein expression from a chicken β-actin promoter.  Cell lines were transiently 
transfected with plasmid DNA using Lipofectamine PLUS (Invitrogen, Carlsbad, CA), 
according to manufacturer’s protocol, unless noted otherwise. 
 
GEL ELECTROPHORESIS, COOMASSIE STAINING, AND WESTERN BLOTTING 
Protein samples were analyzed via 15% SDS-PAGE, unless otherwise noted. For 
recombinant protein expression, protein samples were taken pre- and post-induction to 
visualize protein expression via Coomassie staining. For Western blot analysis, 
immunoprecipitated protein was transferred to polyvinylidene difluoride (PVDF) 
membrane (Fisher) at 50V for 80min. After blocking with Odyssey block buffer (LI-Cor), 
membranes were incubated with anti-Hendra F mouse monoclonal antibody 5G7 at a 
1:3000 dilution in Tris-buffered saline with 0.05% Tween 20 (TBS-T). Membranes were 
washed with TBS-T and incubated with horseradish peroxidase-conjugated goat anti-
mouse (light chain specific) secondary antibody (Jackson Immuno Research) diluted 
1:10,000. Membranes were washed again with TBS-T, developed with SuperSignal West 
Pico Chemiluminescent substrate (Thermo Fisher) and visualized with the Bio-Rad 
ChemiDoc system.  
 
SYNCYTIA ASSAY 
Subconfluent Vero cells in 6-well plates were transiently transfected with pCAGGS-
Hendra F and pCAGGS-Hendra G at a ratio of 1:3 using Lipofectamine and Plus Reagent 
(Invitrogen) per manufacturer’s protocol. Syncytia formation was observed 24 to 48h 
post transfection. Images were taken using a Nikon digital camera mounted atop a Nikon 
TS100 microscope with 10X objective. The fusion index (f) was calculated as f=[1-
(C/N)], where C is the number of cells in a field after fusion and N is the number of 
nuclei.  
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SURFACE BIOTINYLATION 
Vero cells (confluency 80-90%) in 60-mm dishes were transiently transfected using 
Lipofectamine and Plus reagent (4 µg of DNA wild-type or mutant pCAGGS-Hendra F) 
according to manufacturer’s protocol. Eighteen to twenty-four hours post-transfection, 
cells were washed with PBS and starved for 45 min in DMEM deficient in cysteine and 
methionine. Cells were then labeled for 3 h with DMEM deficient in cysteine and 
methionine, containing Tran35S-label (100 µCi/mL; MP Biomedicals). Cells were then 
washed 3 times with 3 mL of ice-cold PBS, and surface proteins were biotinylated using 
1mg/mL EZ-Link Sulfo-NSH-Biotin (Pierce) in PBS with rocking for 35min at 4°C 
followed by incubation at room temperature for 15 min. Cells were then washed 2 times 
with ice-cold PBS and lysed with 500 µL of RIPA lysis buffer (100mM Tris-HCl, pH 
7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholic acid, 1mM 
phenylmethylsulfonyl fluoride (Sigma), and 25mM iodoacetamide (Sigma)). Cellular 
lysates were centrifuged at 136,500xg for 15 min at 4°C. The supernatant was removed to 
a 1.5mL microcentrifuge tube, and 4µL of Hendra F C-tail peptide antibody was added 
and incubated for 3h at 4°C with rocking. Proteins were then immunoprecipitated by 
incubating with 30µL of Protein A-Sepharose beads (GE Healthcare) for 30 min. The 
beads were washed with 2X RIPA  + 0.30 M NaCl, 2X with RIPA + 0.15 M NaCl, and 
1X with SDS Wash II (150 mM NaCl, 50 mM Tris -HCl, pH 7.4, 2.5 mM EDTA). After 
the beads were washed, 60 µL of 10% SDS was added, and the samples were boiled for 
10min, removed to a new tube, and repeated with 40 µL of 10% SDS for a total of 
100µL. Ten microliters of the supernatant was removed to analyze the total protein 
population. To the remaining supernatant, 30µL of Streptavidin beads (Pierce) and 
400µL of biotinylation dilution buffer (20 mM Tris (pH 8), 150mM NaCl, 5mM EDTA, 
1% Triton X—100, 0.2% bovine serum albumin) were then added for 1 h at 4°C with 
rocking. Hendra F was analyzed by 15% SDS-PAGE and visualized using the Typhoon 
imaging system (GE Healthcare). Band densitometry using ImageQuant 5.2 was 
performed for each experiment to quantitate the amount of F expressed, which was 
reported as % expression, the sum of F0 and F1, normalized to WT (Fig 2.1).  
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TIME COURSE IMMUNOPRECIPITATION 
Wild-type Hendra virus F or TM mutants were transiently expressed in subconfluent 
Vero cells using Lipofectamine Plus (Invitrogen) as previously described. The next day 
cells were washed with PBS and starved for 45min at 37°C in cysteine-methionine-
deficient DMEM. Cells were then labeled for 30min with Trans[35S] metabolic label 
(100µCi/mL; MP Biomedicals). At appropriate time points, cells were washed three 
times with PBS and lysed with RIPA lysis buffer, as described. Immunoprecipitation and 
imaging were performed as described for surface biotinylation.  
 
RECOMBINANT PROTEIN EXPRESSION AND PURIFICATION 
SN-TM domain centrifugation constructs were expressed as C-terminal fusions with 
staphylococcal nuclease (Fig 2.2A). All constructs were transformed into Rosetta-Gami 
cells (EMD Chemicals, Gibbstown, NJ) and grown at 37°C in 2X yeast extract-tryptone 
(YT) medium under the selection of 0.015 mg/mL kanamycin, 0.0125 mg/mL 
tetracycline, 0.05 mg/mL streptomycin, 0.034 mg/mL chloramphenicol, and 0.1 mg/mL 
ampicillin. The cultures were grown to an optical density at 600nm (OD600) of 0.6 to 0.8, 
induced for protein expression by addition of 1 mm isopropyl β-d-1-
thiogalactopyranoside (Sigma), grown for 4 h, and harvested by centrifugation. Cells 
were resuspended in a 1:20 culture volume of lysis buffer (50 mm HEPES, 2 mm EDTA, 
1 mm phenylmethylsulfonyl fluoride, pH 8.0), subjected to three freeze-thaw cycles, and 
incubated with 0.1 mg/mL hen egg white lysozyme for 30 min on ice. The cell lysate was 
then sonicated for three-20 s pulses, 5mM CaCl2 was added, and the solution was 
incubated for 30 min on ice. Insoluble protein was pelleted at 12,000 xg for 10 min. The 
supernatant was then purified using the detergent Thesit-290 (Sigma) and a single salt 
(1M NH4OAc) extraction as described previously, except using 50mM HEPES instead of 
20mM Tris-HCl (95). The supernatant containing the recombinant protein was then 
dialyzed overnight at 4°C against lysis buffer containing 0.1M NH4OAc and 0.2% v/v 
Thesit and clarified by centrifugation at 15,000 xg for 15 min. The recombinant protein 
was purified by FPLC cation-exchange chromatography using a 1mL HiTrap SP FF 
column (GE Healthcare) and then exchanged into a solution containing 200mM NaCl, 20 
mM Na2HPO4/NaH2PO4 (pH 7), 29% D2O, and Zwittergent detergent 3-(N,N-
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dimethylmyristyl-ammonio)propanesulfonate (C14SB) (Sigma), as previously described.  
Protein was dialyzed using Slide-A-Lyzer MINI dialysis units (10,000 MWCO; Pierce) 
and concentrations were determined by spectrophotometry, using ε280=17,420 M-1cm-1.  
 
ANALYTICAL ULTRACENTRIFUGATION 
Sedimentation equilibrium (Fig 2.2) measurements were obtained at three different rotor 
speeds using a Beckman XL-A analytical ultracentrifuge equipped with an An-60 Ti rotor 
operated at 25°C. Protein concentrations corresponding to 280nm absorbance between 
0.4 and 0.8 were utilized for determination of the best fit models. Attainment of 
sedimentation equilibrium was established as previously described (95). The buffer 
density was matched to that of C14SB detergent (ρ = 1.04 g/mL) using D2O, as described 
previously (95). The partial specific volume of each protein was estimated using 
SEDNTERP, and data analysis was performed using KaleidaGraph (Synergy Software) 
and HeteroAnalysis. Molecular weight values were fixed for analysis.  
 
THERMAL TRIGGERING ASSAY 
Subconfluent Vero cells in 60-mm dishes were transiently transfected with 4 µg of either 
wild-type or mutant Hendra F in pCAGGS using Lipofectamine and Plus (Invitrogen) 
according to the manufacturer’s instructions. Eighteen to twenty-four hours after 
transfection, cells were washed and replenished with DMEM + FBS at 37°C, or at 50°C. 
Samples treated with warmed media were then incubated in a 50°C water bath for 20 
min. After heat treatment, the samples were immediately placed on ice and the media was 
replaced with ice-cold DMEM + FBS. Following a 30 min incubation on ice, cells were 
washed 2X with ice cold PBS, and incubated with 5 µg/mL mAb 5B3 in PBS + 1% BSA 
for 3 hr at 4°C to detect pre-fusion Hendra F. Cells were then washed 2X with ice cold 
PBS, lysed with RIPA + 0.15M NaCl, and centrifuged for 15 min at 136,500 xg. The 
resultant supernatant was immunoprecipitated using protein G Sepharose beads, and 
protein was analyzed via 15% SDS-PAGE. Hendra F was detected via Western blot 
analysis using mAb 5G7.  Results were reported as % triggered 
=100 �1 − 𝐹𝐹 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑎𝑎𝑎𝑎 55℃
𝐹𝐹 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑎𝑎𝑎𝑎 37℃
�. 
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CO-EXPRESSION OF F PROTEIN WITH TM CONSTRUCTS 
Subconfluent Vero cells in 35-mm dishes were transiently transfected with a total of 2ug 
of DNA. The DNA was transfected at a ratio of 2:1 (F:TM) for HeV F or PIV5 F with the 
TM constructs. For the control without the TM construct, HeV F or PIV5 F were co-
transfected with empty pCAGGS at a ratio of 2:1. Eighteen to twenty-four hours post-
transfection, cells were washed with PBS and starved for 45 min in DMEM deficient in 
cysteine and methionine. Cells were then labeled for 3 h with DMEM deficient in 
cysteine and methionine, containing Tran35S-label (100 µCi/mL; MP Biomedicals). Cells 
were washed 2x with PBS and lysed with RIPA + 0.15M NaCl, as described for the 
surface biotinylation. The HeV F co-expression samples were immunoprecipitated with 
an antibody to the C-tail of HeV F, and the PIV5 F samples were immunoprecipitated 
with an antibody to the C-tail of PIV5 F. Samples were treated as described for surface 
biotinylation, run on a 15% gel, exposed to a phosphor-screen and imaged on the 
Typhoon imaging system (GE Healthcare). Band densitometry was performed with the 
ImageQuant software.  
 
PEPTIDE INHIBITION ASSAY  
Virus, either rgHMPV or PIV5-GFP, was pretreated for 30 min at room temperature with 
TM peptide corresponding to the TM domain sequence of the PIV5 F protein. The 
peptide was synthesized by LifeTein with the following sequence: 
VLSIIAICLGCLGLILILLSVVVWKLL. The peptide was solubilized in sterile DMSO. 
Virus was diluted in OPTI-MEM for an infection with an MOI=1.   Vero cells (70-90% 
confluency) were washed twice with PBS and incubated with 500µL of peptide treated 
virus for 4h at 37°C. After the incubation, the infection media was removed, cells were 
washed 2X with PBS, and cells were left overnight with DMEM+FBS. The following 
day, cells were imaged for GFP-positive cells with a Nikon Axiovert-100 microscope. 
GFP-positive cells were counted and normalized to determine peptide inhibition.  
 
IMMUNOFLUORESCENCE 
Cells grown in 6-well plates containing coverslips were transfected with HeV F. After 
24hr, cells were washed in phosphate buffer saline (PBS) and fixed in 4% 
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paraformaldehyde for 15min at room temperature. Cells were then permeabilized in 1% 
Triton X-100 for 15min at 4°C followed by blocking in 1% normal goat serum and 
incubation with the corresponding primary antibody overnight at 4°C. The following day, 
cells were washed with 0.05% tween-PBS, secondary antibodies were added, and cells 
were incubated at 4°C for one hour. Coverslips were then mounted on glass slides using 
Vectashield mounting media (Vectorlabs, Burlingame, CA). Pictures were taken using a 
Nikon 1A confocal microscope and analyzed with the NIS-Elements software. All images 
were processed in Adobe Photoshop, with equivalent adjustments made to all panels.   
 
SEQUENCE ANALYSIS 
The sequences of 140 paramyxovirus F proteins were aligned and analyzed. First, the TM 
domains were predicted with the TMHMM Server v 2.0. Next, the sequences were 
aligned using the MUSCLE aligner based on similarity that is built into the Virus 
Pathogen Database and Analysis Resource (VIPRBRC) and cross-validated by the 
predicted TM domain regions.  Finally, the frequency of β-branched amino acids was 
calculated at each position in the aligned TM domain region and graphed. 
 
STATISTICAL ANALYSIS 
Statistical significance for the triggering analysis quantitative data obtained was analyzed 
in GraphPad using Student's t test (**, p < 0.05). 
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Figure 2.1. Surface biotinylation. Vero cells were transfected with the construct of 
interest. 24h later cells were starved and radiolabeled with 35S. After the label, cell 
surface proteins were biotinylated. Lysed cells were first immunoprecipitated with the 
HeV F C-tail antibody to pull down the total fusion protein population. A sample of the 
total population was aliquotted, and the remaining sample was immunoprecipitated with 
streptavidin to pull down the surface population.  
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Figure 2.2. Sedimentation equilibrium analytical ultracentrifugation. A. Chimeric 
proteins were designed with the protein staphylococcal nuclease (SN) and the TM 
domain of interest. B. Upon centrifugation, the samples were brought to equilibrium and 
absorbance values were recorded. C. The data obtained was then fit to the equation 
shown to determine best fit, where α is the absorbance, r is the radial position, ro is the 
reference position, M is the molecular weight, ?̅?𝑣 is the partial specific volume, ρ is the 
solution density, ω is the rotor speed, and ζ is the offset coefficient.  Figure modified 
from E.C. Smith.  
 
 
 
 
 
 
 
 
 
 
A. B. 
C. 
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CHAPTER 3: HENDRA VIRUS FUSION PROTEIN TRANSMEMBRANE DOMAIN CONTRIBUTES 
TO PRE-FUSION PROTEIN STABILITY 
 
INTRODUCTION 
 
Enveloped viruses, including members of the paramyxovirus family, such as 
measles virus, mumps virus, Sendai virus, and the zoonotic Hendra virus (HeV), utilize 
surface membrane proteins to promote the vital steps of attachment and membrane 
fusion. Membrane fusion of the viral envelope and target cell membrane, a critical early 
step in infection, is driven by large conformational changes in surface viral fusion (F) 
proteins. The paramyxovirus F protein is a prototypic class I fusion protein that is 
initially synthesized as a homo-trimer in a metastable pre-fusion conformation (96). The 
Hendra and Nipah virus F protein is synthesized in the secretory pathway, trafficked to 
the plasma membrane, endocytosed for cleavage and trafficked back to the cell surface in 
the fusogenically active conformation, F1+F2 (53). Through this entire process, the F 
protein must maintain the pre-fusion conformation. Upon triggering, the F protein 
irreversibly folds into a post-fusion conformation, a change that includes dramatic 
rearrangement of the ectodomain. Stabilization of the pre-fusion conformation is critical 
for viral stability and function, as premature triggering would result in a fusion dead viral 
particle. Understanding factors that control the stability of the pre-fusion conformation 
therefore would provide an avenue for disrupting viral membrane fusion.  
To obtain the pre-fusion structure of the paramyxovirus parainfluenza virus 5 
(PIV5) F protein, a trimeric coiled coil was engineered and added to the soluble portion 
of the fusion protein. Without the coiled coil, the PIV5 F protein could only be 
crystallized in the post-fusion conformation. This suggests that the F protein requires a 
domain to pin the protein in its pre-fusion conformation, implicating the TM domain in  
 
Portions of this chapter were adapted and reprinted by permission from American 
Society for Microbiology: Webb S, Nagy T, Moseley H, Fried MG, and Dutch RE. 
2017. Hendra virus fusion protein transmembrane domain contributes to pre-fusion 
protein stability. J Biol Chem. Epub ahead of print. 
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pre-fusion protein stability (50). A recent study found that soluble HIV gp41 trimers, 
another class I fusion protein, could only be produced when the trimerization tag, foldon, 
was added to the protein (97). TM domains of viral F proteins have historically been 
characterized solely as membrane anchors. However, recent studies have shown that 
changes in length or single point mutations in the TM domain can result in modulation of 
class I, II, and III viral fusion protein expression and activity (86, 98-102). Despite these 
studies, the mechanism by which these mutations alter F protein activity and function 
remains unclear. Although the TM domain of these proteins appears to be important, few 
studies have directly analyzed TM-TM interactions, which is likely a result of the 
difficulty of working with such hydrophobic domains. One study utilized NMR to 
demonstrate that the HIV gp41 TM domain forms a trimer in bicelles, further implicating 
the importance of TM-TM interactions (103). Additionally, TM-TM interactions have 
been shown to be important in several biological systems, including signaling processes 
mediated by receptor tyrosine kinases, so understanding factors that affect TM-TM 
interactions could be implicated beyond viral membrane proteins (104-106). 
A critical role for the TM domain in stability of the pre-fusion form was recently 
proposed for the herpes simplex virus gB (107), and several studies support the concept 
that viral fusion protein TM domains can self-associate, though the TM domain 
oligomeric form could not be determined with the assays utilized (108-110). Previously, 
our group utilized sedimentation equilibrium analytical ultracentrifugation (SE-AUC) to 
directly assess isolated TM-TM interactions. We were the first to demonstrate that 
paramyxovirus F protein TM domains self-associate in monomer-trimer equilibrium in 
the absence of the rest of the protein (95). Molecular dynamic simulations of influenza 
virus HA and HIV envelope glycoprotein TM domains support trimeric interactions, 
suggesting that stabilizing trimeric TM domain interactions may be characteristic of 
many viral fusion proteins (108, 111). Here, we analyzed the sequences of 140 TM 
domains from 19 paramyxovirus species and identified the presence of a β-branched 
residue heptad repeat. To understand what drives TM interactions in the Hendra virus F 
protein, the TM domain sequence was analyzed for association motifs; a heptad repeat 
leucine-isoleucine zipper (LIZ) was found in frame with the upstream leucine zipper in 
the heptad repeat B (HRB) domain. Studies have previously shown that a LIZ motif can 
31 
 
promote protein oligomerization in soluble proteins, and more recently in hydrophobic 
environments (112, 113). Mutagenesis indicated that the HeV F LIZ is important for TM-
TM interactions, as well as overall protein expression and stability. More specifically, 
mutation of the F protein LIZ motif resulted in reduced stability of the pre-fusion 
conformation of HeV F, suggesting TM-TM interactions are important contributors to 
pre-fusion F protein stability. Together, our results suggest that disruption of HeV F TM-
TM interactions affects the pre-fusion conformation of F, and contributes to the F protein 
triggering process that is required to drive membrane fusion. 
The results presented here represent an effort on the part of several people. 
Andreea Popa identified the leucine/isoleucine zipper in the HeV F TM domain and 
performed initial transient transfection experiments of the mutants. She produced the 
HeV F TM mutations in the pCAGGS vector, which I subcloned into the pET11a vector 
for SE-AUC analysis. The sequence alignment was performed by Tamas Nagy, an 
undergraduate that worked in collaboration with our group and Dr. Hunter Moseley’s 
research group. 
 
RESULTS 
 
Identification and oligomeric analysis of a L/I zipper in the HeV F TM domain 
In order to further define elements which drive TM-TM interactions in Hendra F, 
we analyzed the TM domain sequence for motifs involved in protein-protein association 
and identified a heptad repeat leucine-isoleucine zipper that continued through the TM 
domain in frame with the leucine zipper of the upstream HRB domain (Fig 3.1A). 
Previous studies have demonstrated that L/I zippers can mediate protein-protein 
interactions in soluble proteins via hydrophobic collapse (112, 114-116). This motif was 
also found to contribute to protein interactions in a membrane environment via a knob-in-
hole packing mechanism (113, 117). To determine whether this motif could be involved 
in TM-TM association in other viruses, the sequences of 140 paramyxovirus F proteins 
were analyzed for amino acid frequency in the predicted TM domain (Fig 3.2). This 
analysis was composed of 19 unique viruses with multiple strains of each, representing 
each paramyxovirus genus except respirovirus (Table 3.2). The predicted TM domains 
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were aligned to look for a specific pattern related to a L/I zipper. Upon examination, a 
heptad repeat of β-branched residues (isoleucine, valine, threonine), which also included 
leucine, was identified (Fig 3.1B and table 3.2). This suggests that a heptad repeat, such 
as a L/I zipper, may be important for the TM domain across the viral family. To 
determine whether the predicted L/I zipper in the Hendra F TM domain contributed to 
TM-TM association, site-directed mutagenesis was used to replace the four L/I residues 
(L488+I495+I502+L509) with alanine resulting in a four point mutant, LIZ 4A. To 
directly analyze TM-TM interactions, we utilized chimeric proteins containing 
staphylococcal nuclease (SN) protein linked to the TM domain of interest and analytical 
ultracentrifugation, as previously described (95). The addition of SN aids in 
solubilization of the highly hydrophobic TM protein and also increases the extinction 
coefficient of the protein, which is important for absorbance based assays. Samples of the 
wild-type SN-TM and LIZ 4A SN-TM were brought to sedimentation equilibrium in a 
Beckman XL-A analytical ultracentrifuge, and radial absorbance data were obtained at 
20,000, 25,000, and 30,000 rpm. The data were subjected to non-linear least squares 
fitting with equations modeling monomer and monomer-trimer sedimentation equilibria, 
as well as residual plotting with KaleidaGraph. Consistent with previous results, the data 
for the chimeric WT protein fit with a monomer-trimer equilibrium (blue, Fig 3.3A), as 
determined by residual plotting (95, 118). Additional curve fits were analyzed, such as a 
single species monomer (red line Fig 3.3A), but were a poor fit to the absorbance points.  
The chimeric LIZ 4A protein also demonstrated a best fit to a shallow monomer-trimer 
equilibrium curve (Fig 3.3B). When fit to a multi-species system (monomer-Nmer), the 
oligomeric state of the second species for both WT and LIZ 4A was found to be trimeric. 
The data points for LIZ 4A exhibited a shift in absorbance toward a smaller radial 
position suggesting a shift in equilibrium toward a much larger population of monomeric 
protein when compared to WT. To further confirm this shift in equilibrium for the LIZ 
4A chimeric protein, an absorbance based apparent dissociation constant was calculated 
for WT and LIZ 4A. When normalized to WT at each spin speed, the LIZ 4A mutant 
displayed an approximate thousand fold decrease in association constant, suggesting 
weaker TM-TM interactions (Table 3.1). These results implicate the predicted L/I zipper 
motif in TM-TM association for the HeV F TM domain.  
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Mutation of the TM domain L/I zipper alters overall protein expression and fusion 
activity 
The analytical ultracentrifugation data suggested a shift in equilibrium upon 
mutation of the L/I zipper motif in the isolated TM domain, consistent with reduction in 
TM-TM association. To determine how these mutations affected expression, intracellular 
transport, and function, the LIZ 4A mutant protein was analyzed for total and surface 
expression by cell surface biotinylation. The trafficking and cleavage pathway of the F 
protein ultimately results in a homo-trimer that is composed of the F1 and F2 fragments. 
The F2 fragment is small in size, so F1 is used to detect the cleaved, active form of F. 
When compared to the WT F protein, the LIZ 4A F protein exhibited a dramatic 
reduction in total protein expression, as indicated by the reduction in F1 detectable (Fig 
3.4A). A reduction in protein expression of LIZ 4A F at the cell surface was also 
observed (Fig 3.4B), which could potentially affect membrane fusion. The presence of 
cleaved F protein on the cell surface was used as a measure of whether the F protein was 
properly trafficked. In order to test fusion activity, a syncytia assay was performed in 
which F and the attachment protein (G) were transiently transfected into cells, and the 
cells were visualized for the presence of syncytia (indicated by white arrows in fig 3.5). 
The LIZ 4A F protein exhibited a striking reduction in fusion index, a measure used to 
quantify fusion activity, with levels comparable to the mock control (Fig 3.5A). The 
complete loss of fusion activity exhibited by the LIZ 4A F protein indicated that the L/I 
zipper may contribute to overall protein stability or alter pre-fusion conformation 
stability. In addition, the single point mutants, L488A, I495A, I502A and L509A, were 
examined to determine the effect each had on the F protein. The single point mutants, 
L488A, I495A and I502A, exhibited a moderate reduction in total protein expression 
compared to the WT F protein (Fig 3.3A). To determine the effect these mutations had on 
membrane fusion, syncytia formation assays were performed. Each of the single point 
mutants displayed a moderate to WT level fusion index (Fig 3.5A&B). The single point 
mutant, L509A presented with a large reduction in total and cell surface protein 
expression levels, similar to that of LIZ 4A (Fig 3.4B). Interestingly, although LIZ 4A F 
and L509A F had comparable reduction in total and surface expression, LIZ 4A exhibited 
a fusion index at background levels, whereas the L509A fusion index was only 
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moderately reduced (Fig 3.4B). Although there was a reduction in expression levels, 
L509A had more fusogenically active F1 than the LIZ 4A mutant, which would enable 
L509A to drive fusion, unlike LIZ 4A (Fig 3.4D). A small shift in molecular weight for 
the LIZ 4A and L509A constructs was observed. This may be the result of altered 
glycosylation, as it has been shown previously that there is a glycosylation site at residue 
N464. The change in TM-TM interactions may affect the glycosylation state of this 
upstream residue (36). Previously, it was shown that there is a correlation between cell 
surface expression and fusogenicity (73). The surface expression of LIZ 4A was around 
50% of WT, however, the level of fusion activity was reduced to near background levels. 
This deviation suggested that LIZ 4A may be affecting overall protein stability. These 
results suggest that even when individual mutations have an impact on protein 
expression, it was the mutation of the four L/I zipper residues which caused a complete 
loss of F protein fusogenic activity. 
 
Mutation of the TM domain L/I zipper affects stability of the full length F protein 
The HeV F protein is trafficked through the secretory pathway and must then 
undergo a unique trafficking pathway through recycling endosomes for processing to the 
fusogenically active form of F by cathepsin L (53). The F protein is synthesized in the 
endoplasmic reticulum as an inactive trimer (F0), trafficked to the plasma membrane, 
endocytosed and cleaved to the fusogenically active form of F (F1+F2). After cleavage, 
the active form of F must then be trafficked back to the plasma membrane (4). With this 
complicated trafficking pathway, the F protein must be stable over time so that it can 
ultimately arrive at the plasma membrane in its active, cleaved form. To test whether the 
LIZ 4A TM mutation affected the stability of the F protein over time, a pulse-chase 
experiment was performed with various time points analyzed up to 24 hours post-
transfection (Fig 3.6). The WT HeV F protein displayed stability over a 24 hour time 
period. At early time points (0-1hr), the F protein was detected as the inactive uncleaved 
form, Fo. Expression levels increased from the 0hr time point. This is likely because the 
C-tail antibody does not recognize partially synthesized protein at the 0h time point. 
Between the two and four hour time points, the F protein was detected in both the 
uncleaved and cleaved forms, suggesting proper trafficking and cleavage of the F protein. 
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Ultimately at the final time points, only the cleaved, fusogenically active form of WT F 
was present (Fig 3.6A). Interestingly, the initial level of LIZ 4A F protein expression at 
the early time points (0 and 0.5hr) were comparable to that of WT, but quickly protein 
levels began to diminish over the later time points. The remaining LIZ 4A HeV F protein 
was processed as expected, but by 1hr post transfection, a decrease in expression was 
evident compared to the WT F protein. At 24 hours post-transfection, there was almost no 
detectable amount of LIZ 4A F present. Band density quantification showed the 
progressive loss of LIZ 4A F over time (Fig 3.6B). The reduction in LIZ 4A F protein did 
not appear to be a result of reduced protein synthesis, but could be attributed to overall 
misfolding of the protein, resulting in targeting for degradation or due to premature 
triggering of F to its post-fusion conformation. It has been suggested previously that 
prematurely triggered F protein is more susceptible to degradation, which could explain 
the reduction in LIZ 4A F detection (119).   
 
Pre-fusion F protein stability is reduced with LIZ 4A mutation 
In order to obtain crystal structures of the pre-fusion conformation of several viral 
F proteins, including PIV5 F, HeV F, and RSV F, trimeric tags were engineered onto the 
protein to prevent triggering to the post-fusion conformation (47, 50, 97, 120). This 
suggested that the F protein may require TM-TM association to maintain the pre-fusion 
conformation, until an appropriate event occurs to promote triggering to the post-fusion 
conformation. The LIZ 4A F protein was utilized to determine whether reduction in TM-
TM association affected F protein triggering. Other groups have previously shown that 
changes in thermal conditions can promote triggering of the F protein (121-123). Based 
on the thermal triggering property of F, a novel assay was developed to test pre-fusion F 
protein stability. After cells were transfected to express the F protein, they were either 
maintained at 37°C or exposed to an elevated temperature of 55°C for a brief period. 
After heat exposure, the cells expressing the WT F protein or LIZ 4A mutant were then 
quickly cooled to prevent further conformational changes and incubated with an 
antibody, mAb 5B3, that was specific to the pre-fusion conformation of HeV F. This 
allowed for immunocapture of the population of F that remained in the pre-fusion 
conformation on the surface of the cell, thus representing the population that would drive 
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membrane fusion. The cells were then lysed and processed to determine the amount of F 
protein in the pre-fusion conformation. The WT HeV F protein was only minimally 
susceptible to thermal triggering at 55°C, as only approximately 15% of the WT protein 
triggered at this temperature (Fig 3.7A). In contrast, the LIZ 4A F protein exhibited a 
dramatic reduction in pre-fusion F detectable, corresponding to approximately 60% of the 
expressed protein triggered (Fig 3.7B). Additional experiments were performed with the 
WT HeV F protein at higher temperatures of 60°C, at which the majority of the WT HeV 
F protein surface population triggered to the post-fusion conformation (Fig 3.8). The 
susceptibility of LIZ 4A F to trigger at temperatures lower than the WT HeV F suggested 
that TM-TM association may contribute to pre-fusion stability of the F protein, with a 
shift in TM-TM association equilibrium resulting in a dramatic effect on the stability of 
the pre-fusion conformation.  
 
DISCUSSION  
 
While paramyxovirus F proteins have been studied extensively, the factors 
driving pre-fusion stability remain unclear. Upon triggering, the F protein undergoes a 
dramatic conformational change, refolding to the post-fusion conformation (Fig 3.9). 
This large, irreversible change in conformation drives membrane fusion between the viral 
and cellular membranes, a critical event in the viral life cycle. It has been shown that 
peptides that prevent conformational changes can be used as a therapeutic treatment, as in 
the case of Enfuvirtide for targeting of HIV gp41 (124).  Maintenance of the pre-fusion 
state of the F protein is necessary until the F protein is in the appropriate location to drive 
membrane fusion. Stabilization of the pre-fusion conformation is therefore critical for 
viral stability and function.  
Although the pre-fusion structure for several viral fusion proteins has been 
obtained, including Nipah virus F, HeV F, HIV env, and the human coronavirus HKU1 
spike protein, the structure of each required modification with a trimeric tag, such as 
foldon or GCNt (47, 97, 125, 126).  TM domains of viral F proteins have historically 
been considered to act primarily as membrane anchors, but these structural studies 
suggest that the TM domain may be important for pre-fusion F stability, as the soluble 
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trimeric tags mimic the proposed function of the TM domain. Previously, we have shown 
that several paramyxovirus F protein TM domains associate in a monomer-trimer 
equilibrium in the absence of the rest of the protein (95). In addition, replacement of F 
protein TM domains with foreign TM sequences, including a poly-leucine stretch, can 
result in folding defects (90, 127, 128). The TM domain of the measles virus F protein 
was found to modulate fusion activity by altering F protein interaction with its receptor 
binding protein, hemagglutinin (102).  These studies suggest that the TM domain 
sequence and TM-TM interactions are specific and important for the stability of the F 
protein. Results from the data presented here further support the importance of the TM 
domain in F protein function and suggest that TM-TM interactions are important for HeV 
F protein stability and function. More importantly, these results demonstrate the 
significance of TM-TM association in the stability of the pre-fusion conformation of F, a 
critical point of control for viral membrane fusion.  
A L/I zipper was identified in the TM domain of HeV F in frame with the 
upstream heptad repeat B domain. Here, sedimentation equilibrium analytical 
ultracentrifugation demonstrated that mutation of the L/I zipper motif resulted in reduced 
TM-TM association when the TM domain was studied in isolation. Previously, motifs 
responsible for TM-TM association in cellular transmembrane proteins include the 
GxxxG motif, polar amino acids, Ser/Thr clusters, and QxxS motifs. The GxxxG motif 
has been suggested to promote TM-TM interactions in the HIV env protein (129-131).  
Identification of an L/I zipper motif is a novel association motif for viral F protein TM 
domains (114). The sequence analysis of 140 paramyxoviruses revealed a heptad pattern 
of β-branched residues, suggesting that TM association motifs may be more flexible than 
strictly a leucine/isoleucine zipper. Mutation of the L/I zipper also resulted in alteration 
of overall protein stability and fusion activity, suggesting that TM-TM interactions are 
important for proper F protein function. The mutation of the entire L/I zipper 
dramatically reduced transient protein expression levels, abolished fusion activity and 
overall protein stability as demonstrated via pulse chase experiments. The L/I zipper and 
similar motifs could also be involved in TM-TM association of other class I viral fusion 
proteins, but there may be multiple motifs within a single TM domain that maintain TM-
TM association.  
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Considering the requirement of a trimerization tag for crystallization of several 
paramyxovirus F proteins in the pre-fusion conformation, it is reasonable to predict that 
TM-TM interactions are involved in maintaining pre-fusion F protein stability. Various 
groups have previously shown that thermal treatment can be utilized to trigger the fusion 
protein to its post-fusion conformation. This characteristic of the F protein was used to 
develop an assay that  demonstrated that mutation of the L/I zipper in the HeV F TM 
resulted in a protein that was dramatically less stable in the pre-fusion conformation. It is 
important to remember that the F protein must ultimately trigger and drive membrane 
fusion, so equilibrium must be maintained with TM-TM interactions not being too strong 
or too weak. The results here suggested that shifting the TM-TM interactions toward a 
monomeric state dramatically destabilized the pre-fusion conformation of the F protein. 
The proposed model suggests that TM-TM interactions are important for stability of the F 
protein in its pre-fusion conformation (Fig. 3.9). We hypothesize that, on the other end of 
the spectrum, if TM-TM interactions are too strong, the F protein will not be able to 
trigger to the post-fusion conformation. Here we propose that TM-TM interactions could 
also be important in vivo, and that modulation of those interactions may result in a fusion 
dead particle, as a result of premature triggering of the F protein. Together, these results 
suggest that TM-TM interactions serve to pin the F protein in its pre-fusion conformation, 
though a dynamic equilibrium ultimately allows triggering.  
Beyond viral F proteins, TM-TM interactions have been shown to be important in 
several cellular processes. A number of studies have shown that TM-TM interactions are 
necessary for proper signaling of receptor tyrosine kinases, such as ErbB/Neu receptors 
and EGFR. A recent report found that targeting the ErbB TM domain with TM domain 
derived peptides could delay tumor growth (105, 132). Additionally, the β-amyloid 
peptide, which helps mediate plaques typical of Alzheimer’s disease lesions, was found 
to contain critical TM domain residues that contribute to β-amyloid peptide 
oligomerization (133). The identification of a L/I zipper in the TM domain of the Hendra 
viral F protein may provide insight into motifs responsible for TM-TM association in 
cellular proteins. These studies implicate the TM domain as not just an anchor in the 
membrane, but more importantly as a domain essential for the function of the full length 
viral F protein. When considering methods for targeting the viral F protein for therapeutic 
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purposes, it may be reasonable to consider targeting the TM domain, as it has been shown 
here to contribute to pre-fusion stability and overall F protein function.  
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Figure 3.1. LIZ motif in HeV F TM domain. A. Diagram of the fusogenically active, 
disulfide linked heterodimer F protein with the HeV F TM sequence below. Domain 
structure of F includes the fusion peptide (FP), heptad repeat A and B (HRA, HRB), 
transmembrane domain (TM), and the cytoplasmic tail (CT). Mutations for the LIZ 4A 
HeV F construct are indicated in red in the sequence below WT F. Andreea Popa 
identified the LIZ and designed the mutations in the pCAGGS expression vector. B. The 
frequency of β-branched residues in the predicted TM domains of 140 viruses in the 
paramyxovirus family is shown graphically and appears in a heptad repeat pattern 
(positions 480-510). Tamas Nagy performed the sequence alignment and determined the 
frequency of β-branched residues. 
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Figure 3.2. Amino acid frequency in the TM domain of 140 paramyxoviruses. The 
intensity of each square represents the frequency of the residue.  
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Figure 3.3. Sedimentation equilibrium analysis revealed a shift in monomer-trimer 
equilibrium for LIZ 4A SN-TM. Samples were prepared in C14SB detergent micelles, 
and absorbance data were collected at 20,000 rpm in a Beckman XL-A analytical 
ultracentrifuge. WT SN-TM (A) and LIZ 4A (B) data points fit to a monomer (red line) 
and monomer-trimer (blue  line) model. Residual fitting is shown above for both curve 
fits, with monomer residuals in red and monomer-trimer residuals in blue.   
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Table 3.1. Best fit model and relative apparent association constant (Ka*) for 
purified SN-TM constructs. Analysis was performed at three different speeds. Data are 
shown for monomer and monomer-trimer curve fits. Based on χ2 and residual fitting, the 
monomer-trimer curve fit was most appropriate for WT and LIZ 4A. The relative 
apparent association constant (Ka) is normalized to the WT SN-TM construct for each 
spin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Speed (rpm): 20,000 25,000 30,000 
Construct: WT LIZ 4A WT LIZ 4A WT LIZ 4A 
Monomer fit: 
χ2 0.0424 0.0485 0.2184 0.0971 0.0504 0.0221 
R 0.990 0.972 0.982 0.972 0.993 0.981 
Monomer 
Trimer fit: 
χ2 0.00184 0.00236 0.00305 0.00180 0.00303 0.00174 
R 1.000 0.999 1.000 0.999 1.000 0.999 
Ka* 1 2.39 x 10-3 1 8.37 x 10-2 1 4.11 x 10-2 
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Figure 3.4. Total and surface expression levels for LIZ 4A F. Total protein (A) and 
cell surface (B) expression levels of transiently transfected F constructs after a 3h 
metabolic label, surface biotinylation and immunoprecipitation. C. Total (black bars) and 
surface (white bars) expression levels of F0+F1 were determined by densitometry and 
normalized to WT levels. D. The amount of cleaved F was determined by densitometry as 
F1/(F0+F1). The average represents three independent experiments. Each mutant was 
compared to the WT F protein using the Student’s t test. *, p<0.05; **, p<0.005; ***, 
p<0.0005 
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Figure 3.5. The LIZ 4A mutation completely abolished F-mediated fusion activity. 
A. Vero cells were transfected with the HeV G attachment protein and WT F, or each of 
the L/I zipper mutants. Syncytia formation was analyzed 24 h post transfection; images 
were taken with a Nikon TS100 microscope. White arrows indicate syncytia. Images are 
representative and quantification (B) represents three independent experiments. **, 
p<0.005 
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Figure 3.6. LIZ 4A F was less stable over time than the WT F. A. A pulse chase 
experiment was performed to monitor WT F or LIZ 4A F protein expression and 
processing. After a 30 min metabolic label, samples were taken at various time points, 
immunoprecipitated, analyzed on a 15% SDS PAGE, and exposed to a Phosphor screen 
for imaging. B. Quantification of F0+F1 was determined by densitometry and normalized 
to the zero time point for each construct. The average represents three independent 
experiments ± standard deviation. The Student’s t test was used to determine significance 
between WT F and LIZ 4A time points. *, p<0.05; **, p<0.005; ***, p<0.0005 
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Figure 3.7. LIZ 4A F triggered more readily than WT F at 55°C. A. Vero cells were 
transfected with WT or LIZ 4A F, thermally treated, and then antibody specific to the 
pre-fusion conformation of F (mAb 5B3) was directly added to cells. 
Immunoprecipitation was performed followed by Western blot analysis, probing for the F 
protein with mAb 5G7. Thermal triggering was performed at 55°C for both constructs. B. 
Quantification was determined via band densitometry, normalized to 37°C for each 
construct, and reported as % triggered [100*(1-(F expression at 55°C/F expression at 
37°C))]. Results represent three independent experiments. **, p < 0.005  
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Figure 3.8. F protein triggering at 60°C. WT HeV F and LIZ4A HeV F were thermally 
treated and immunoprecipitated to detect the pre-fusion conformation of F, as described. 
The WT F and LIZ 4A F were not detectable in the pre-fusion conformation after the 
60°C treatment.  
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Table 3.2. Virus and associated accession # for the sequences analyzed in Fig 1B. 
 
Virus Accession # 
Parainfluenza virus 5 YP_138515 
Hendra virus NP_047111 
Nipah virus 
CAD92362 
CAF25496 
AAK50544 
CAD92356 
CAD92350 
AAY43915 
AAK50553 
NP_112026 
 
Avian paramyxovirus 2 ACA49108 
Avian paramyxovirus 3 ACB46870 
Avian paramyxovirus 4 
ACF60577 
ACJ06714 
Avian paramyxovirus 6 
ABQ45546 
NP_150060 
Dolphin morbillivirus NP_945028 
Goose paramyxovirus SF02 NP_872276 
Human parainfluenza virus 2 
BAE00054 
NP_598404 
Mapuera virus YP_001249276 
Measles virus 
AAF85696 
BAA09958 
ABB71661 
BAA33877 
AAA75499 
AAF85672 
BAB60865 
ACA09725 
ABD34000 
BAA09951 
ABY21198 
ABY21190 
BAA33871 
ABK40529 
ABB71669 
BAE98298 
ABD34016 
ABD34008 
AAF85704 
AAV84957 
ABY21214 
ABY21206 
ABA59561 
ABB71645 
ABY21182 
ABB71653 
CAA91368 
AAF85664 
BAA84130 
AAF85688 
AAB26145 
AAF85680 
ACJ66775 
NP_056922 
AAS86263 
Mumps 
AAG37830 
AAV65070 
AAP74196 
ACJ11209 
AAK60061 
AAL83743 
AAT76832 
AAK60097 
AAK83222 
AAK60088 
AAK60070 
ACJ11200 
ABY81901 
ABG36714 
AAK60079 
AAL76265 
BAG84570 
ACH78353 
AAV65061 
AAF70393 
NP_054711 
ABY81893 
AAT81469 
Newcastle disease virus 
AAT42085 
AAX45367 
AAX45397 
ABX57750 
AAX45421 
ABZ80395 
AAX45427 
ABK63993 
AAK55550 
AAT42079 
ABM88264 
CAB51325 
ACB37232 
AAX45403 
AAZ76402 
AAC28374 
ABF18952 
AAU89279 
AAX45391 
AAS67141 
AAS67165 
AAX45409 
AAW30679 
AAT42073 
ABV60359 
ABG29400 
ABY20964 
AAL18935 
ABZ80389 
AAX45385 
ACJ53752 
AAS67147 
ABG29388 
AAO46783 
ACJ53758 
ABG29394 
AAY68572 
AAS67153 
AAS67159 
AAX45415 
AAS67129 
AAX45379 
ABH10572 
AAZ76408 
ABG56152 
AAX45373 
AAS67135 
AAW62249 
NP_071469 
Pigeon paramyxovirus 1 CAI56196 
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Peste-des-petits-ruminants virus 
CAJ01699 
AAS68030 
ABX75303 
ABY71270 
ABX75311 
YP_133826 
 
Porcine rubulavirus YP_001331033 
Rinderpest virus 
CAA83181 
YP_087124 
Simian virus 41 YP_138508 
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Table 3.3. TM domain heptad repeat alignment. F protein TM domain sequence three 
different paramyxovirus genera, highlighting the heptad repeat of β-branched and leucine 
residues. The TM domain was predicted with the TMHMM server v 2.0. 
 
Genera Virus Accession # Predicted TM sequence 
Morbillivirus Rinderpest  CAA83181 
.TGH ILVGAGL IAVVGIL IVTCCC. 
Measles  AAF85672 GLSS TSIVYIL IAVCLGG LIGIPAL I...... 
Rubulavirus 
Mumps  AAG37830 .IGA IIIAALV LSVLSII ISLLFCC  
Parainfluenza 
virus 5 
YP_138515 .... LSIIAIC LGSLGLI LIILLSV VVW.... 
Avulavirus 
New castle 
disease virus 
AAT42085 .... LTSTSAL ITYIVLT TIALICG IVSLVLT 
Avian 
paramyxovirus 
2 
ACA49108 .... TSIIVLC VLAALII VWLIALT VCFCY.. 
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Figure 3.9. Proposed model: TM-TM association affects triggering. Viral fusion 
proteins undergo a large conformational change upon triggering. TM-TM interactions are 
important for maintenance of the pre-fusion conformation. Reduced TM-TM association 
results in prematurely triggered F protein, while TM-TM association that is too strong 
may prevent triggering to the post-fusion conformation. A dynamic equilibrium must 
therefore be maintained in order for the F protein to properly trigger for membrane 
fusion.  
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CHAPTER 4: TARGETING THE F PROTEIN TM DOMAIN TO INHIBIT MEMBRANE FUSION 
 
INTRODUCTION 
 
Membrane proteins represent approximately 30% of all proteins encoded by the 
human genome and are important for many aspects of cell biology and physiology. Not 
surprisingly, it is estimated that about 50% of current drug targets are membrane proteins. 
Despite the clear importance of membrane proteins in cellular biology, their composition 
of both hydrophobic transmembrane regions and hydrophilic soluble domains have made 
it difficult to obtain structural data, with only 3,084 of 126,722 protein data bank (PDB) 
entries representing membrane proteins (PDBTM). Both cellular and viral membrane 
proteins are typically anchored to the membrane through a transmembrane domain, which 
has been shown to serve as more than an anchor and contributes to the function of the 
protein. The difficulty of working with highly hydrophobic transmembrane domains has 
previously excluded these domains from being targeted for therapeutic development. 
However, advancements in understanding the TM domain of these proteins have recently 
been aided by improvements in cryo-electron microscopy and NMR. The TM domain of 
HIV gp41 was revealed as two helices linked by a flexible region, based on high 
resolution NMR data (134). Previously, a GxxxG motif was identified within the TM 
domain of gp41 and found to be important for self-assembly of the TM domains in a 
membrane environment. Virus-cell fusion was also found to be inhibited when cells 
treated with homologous gp41 TM peptide were infected with virus (131). Based on the 
structure of the TM domain, rational drug design may now be used to more accurately 
target the gp41 TM domain and potentially modulate fusion. 
The life cycle of enveloped viruses requires the fusion of the viral envelope with a 
target cell membrane. The fusion protein is essential for viral entry and, therefore, has 
been studied to aid in development of antivirals. There are several points in the early 
stages of the fusion process that can be targeted for disruption: the binding step mediated 
by the attachment protein, the interaction between the attachment protein and fusion 
protein that mediates triggering, and the overall refolding of the fusion protein. While 
there is little sequence homology among class I fusion proteins, the steps critical for 
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membrane fusion appear to be conserved. Although the role the ectodomain plays in 
fusion has been studied for a long time, only recently has the role of the TM and 
intraviral domain been studied. Class I fusion proteins, including those of the 
paramyxovirus family, are ultimately folded as trimers and it has been shown that the TM 
domain is important for proper folding and function of the F protein. Replacement of the 
TM domain with other F protein TM domains or lipid anchors alters F protein function. 
Additionally, mutation of motifs known to promote protein oligomerization, such as 
GxxxG motifs, resulted in incomplete fusion (129, 135). The importance of TM 
oligomerization can also be seen with cellular proteins. For example, the protein 
ultimately responsible for plaque formation and development of Alzheimer disease, 
amyloid precursor protein (APP), must dimerize for the generation of amyloid-β (Abad, 
2009). Neuropilin-1 (NRP1), a coreceptor for vascular endothelial growth factor receptor 
2 (VEGFR2), represents another example in which the TM domain is important for 
function and the oligomeric status of the protein is important. The NRP1 TM domain 
contains a GxxxG motif that is required for dimerization and ultimately downstream 
signaling. It has been shown that targeting the NRP1 TM domain with synthetic peptides 
could inhibit glioma tumor growth in vivo (136). Together, these studies exemplify the 
potential of targeting the transmembrane domain of proteins for therapeutic drug design.  
Previously, we have shown that the TM domain of the HeV F protein associates 
in isolation and contributes to overall protein stability. To further understand the role of 
the TM domain in protein folding, stability or membrane fusion, the TM domain was 
targeted as a potential modulator of membrane fusion. Since the TM domain has been 
shown to be important for F protein function and self-associates, it was hypothesized that 
introduction of exogenous TM protein would disrupt the TM-TM interactions in the 
native F protein, resulting in premature triggering or protein misfolding. To test this, 
exogenous Hendra F TM constructs were co-expressed with the wt F and overall protein 
expression was analyzed. Co-expression of the exogenous Hendra F TM constructs 
dramatically reduced the expression of Hendra F.  However, the co-expression of 
exogenous Hendra F TM constructs with PIV5 F did not have a dramatic effect on PIV5 
F expression levels, suggesting that the interaction of the exogenous TM constructs is 
sequence specific. Additionally, a TM peptide homologous to the PIV5 F TM domain 
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was used to inhibit viral infection in cells. Together, these results further emphasize the 
importance of the TM domain in the F protein function and also identify the TM domain 
as a potential antiviral target.  
 
RESULTS 
 
Exogenous TM constructs reduced HeV F expression 
 To test whether the TM domain of the fusion protein could be targeted, exogenous 
TM constructs were designed based on the HeV F protein sequence. Three constructs 
were designed containing a signal peptide, a variable linker, the full length TM domain 
and C-tail linked to an HA-tag (Fig 4.1B). A signal peptide was included to target the 
protein to the endoplasmic reticulum because during translation the HeV F protein is co-
translationally inserted into the endoplasmic reticulum. The variable linker represented 
varying lengths of the HRB domain upstream of the TM domain and denoted as short 
linker, long linker or HRB TM (Fig 4.1C). These constructs were then co-expressed with 
the full length HeV F protein in Vero cells at a DNA transfection ratio of 2:1 (F:TM). A 
radiolabel surface biotinylation was used to determine the expression levels of HeV F, as 
well as whether the F protein was trafficked to the cell surface. When HeV F was co-
expressed with an empty vector as a control, the F protein was as two bands, F0 
(uncleaved) and F1 (cleaved) in both total overall expression and the surface population 
(Fig 4.2 A&B). Upon co-expression of each of the TM constructs, total and surface 
expression of HeV F was reduced to 20-30% when compared to the HeV F expressed 
with empty vector (Fig 4.2C).  
In addition to expression levels, the proteolytic processing of F was analyzed by 
calculating cleavage (F1/(F0+F1)).  HeV F co-expressed with the empty vector resulted in 
approximately 40% cleavage in the total and surface populations (Fig 4.2D). Co-
expression of the short and long linker TM constructs with HeV F significantly reduced 
cleavage in the total population to approximately 26% and 27%, respectively. 
Interestingly, the amount of cleaved protein detected on the surface was only 
significantly reduced when HeV F was co-expressed with the long linker TM. To 
determine whether the effect was concentration dependent, HeV F and the short linker 
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TM was co-expressed at additional ratios of 10:1 and 20:1. As the amount of HeV F 
DNA transfected was increased the levels of HeV F detected also increased, as expected 
(Fig 4.3A). However, the levels of TM detected did not change, which could be a result 
of quick turnover of the small TM protein. A time course analysis was performed to 
determine whether the initial synthesis of HeV F was reduced upon co-expression of the 
TM constructs, or if the presence of the TM proteins reduced the stability of the F protein 
over time. At the zero time point, the levels of HeV F detected when co-expressed with 
the short linker TM is reduced when compared to the co-expression with empty vector 
(Fig 4.3C). It is important to note that the F protein cannot be detected until it is fully 
synthesized because the antibody used for immunoprecipitation detects the C-tail. The 
protein that is synthesized undergoes cleavage, producing fusogenically active F1, as seen 
in the 2 hr and later time points. Quantification of these preliminary results suggests that 
the co-expression of the short linker TM correlates with an increased rate of protein 
degradation. The F0+F1 expression levels immediately start to decrease at the 1hr time 
point (Fig 4.3D). Overall, the addition of the homologous TM constructs resulted in a 
dramatic reduction in HeV F protein expression.  
 To further characterize the co-expression, immunofluorescence was used to 
determine whether the exogenous TM constructs were localized in the same 
compartments of the cell as the HeV F protein. When HeV F was co-expressed with 
empty vector in Vero cells, the F protein was primarily detected near the nucleus by a 
monoclonal antibody to the F protein (7F7) in what is likely the endoplasmic reticulum. 
For co-expression with the TM constructs, the TM protein was detected with an anti-HA 
antibody (Roche). All three of the TM constructs appeared to express throughout the cell 
and were mostly detected near the nucleus. The overlaid images show that the HeV F 
protein and each of the TM constructs are expressed in similar regions of the cell (Fig 
4.4). This is to be expected, as the TM proteins were tagged with a signal peptide to 
target the protein to the endoplasmic reticulum. Co-immunoprecipitation of HeV F with 
the TM constructs was attempted, however the assay was not successful. This may be the 
result of the dramatic reduction in overall F protein levels. Though a direct interaction 
could not be explicitly determined, the immunofluorescence data suggests that the F and 
TM proteins are expressed in similar regions of the cell.  
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Fusion activity is reduced upon exogenous TM expression 
 Though the presence of the exogenous TM constructs dramatically reduced the 
levels of HeV F detected in cells, there was still a small population of F detected. A 
syncytia fusion assay was used to determine the effect the presence of the TM proteins 
had on F protein function. The F protein and its prototypic attachment protein, G, were 
co-expressed in Vero cells with each of the TM constructs. After 24hr, the cells were 
imaged to visualize syncytia formation. HeV F and G co-expressed with empty vector 
resulted in syncytia formation, as indicated by the white arrows in figure 4. When the TM 
constructs were introduced into the transfection, syncytia formation was ablated (Fig 4.5). 
The reduced overall expression levels of HeV F would explain a reduction in syncytia 
formation. Additionally, co-expression of HeV F with the short linker and long linker TM 
proteins resulted in reduced protein cleavage, further (Fig 4.2D) reducing the presence of 
fusogenically active F protein. The co-expression of the TM constructs resulted in a 
dramatic reduction in membrane fusion activity. Previously, Clint Smith determined the 
correlation between wild-type surface expression levels and the resulting fusion activity. 
Based on his findings, a mutant that expresses at 20-30% when normalized to wild-type 
would be expected to exhibit fusion levels at 30-40% of wild-type. Interestingly, the co-
expression of the TM constructs reduced HeV F expression to these levels, but fusion 
activity was ablated. The lack of fusion seen may be the result of pre-mature triggering of 
the fusion protein, or the presence of the TM proteins could somehow prevent the fusion 
protein from being able to trigger.     
 
The effects of the exogenous TM constructs are specific 
 The previous results demonstrated that the HeV F protein is deleteriously affected 
upon expression of homologous TM constructs. To determine whether the TM proteins 
were specifically targeting the HeV F protein, analogous experiments were performed 
with another class I fusion protein of the paramyxovirus family, PIV5 F. The same DNA 
transfection ratio of 2:1 was used for transfection of PIV5 F with the TM constructs. Co-
expression of the TM constructs with PIV5 F in Vero cells demonstrated no change in 
total F protein expression levels (Fig 4.6A). The PIV5 F protein was able to drive 
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membrane fusion and promote syncytia formation in the presence of the exogenous TM 
constructs, as indicated by white arrows (Fig 4.6B). Together, these data indicate that the 
TM constructs designed based on the HeV F TM domain do not produce the same effect 
when expressed with PIV5 F as co-expression with HeV F, suggesting that the effect may 
be specific.  
 
TM peptide treatment reduces viral infection 
 The results presented thus far have utilized transient transfection to demonstrate 
that the TM domain can be targeted. In order to determine if the F protein TM domain 
could be targeted in a more physiologically relevant system, an infection assay was 
performed. The Hendra virus is a BSL-4 pathogen, so the infection assay was executed 
with two other paramyxoviruses, PIV5 and human metapneumovirus (HMPV), which 
both utilize class I fusion proteins to mediate membrane fusion. The recombinant viruses 
used contained GFP, which allowed for visualization of infection.  A peptide was 
designed based on the sequence of the PIV5 F TM domain and did not include the C-tail 
or HRB domain. The highly hydrophobic peptide was resuspended in DMSO. rgHMPV-
GFP or rgPIV5-GFP were treated with varying concentrations of peptide for 30min and 
then added to Vero cells to allow for infection (MOI=1). After 24hr, the cells were 
imaged to count GFP+ cells. When the viruses were treated with DMSO (0μM peptide), 
the infection for both appears to be widespread. Treatment with TM peptide reduced the 
number of GFP+ cells for PIV5 (Fig 4.7). Addition of 5uM of peptide resulted in 
approximately 50% reduction in PIV5 infection. The HMPV samples treated with peptide 
did not exhibit a reduction in GFP+ cells, suggesting that the TM peptide utilized was 
specific to PIV5. Together, these results suggest that the TM domain can be targeted to 
disrupt F protein function and viral infection.  
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DISCUSSION 
 
 The fusion protein drives the fusion of the viral and cellular membranes, a key 
early step in the entry of enveloped viruses. Previously, various methods have been used 
to disrupt the fusion process: premature triggering of the fusion protein, disruption of 
fusion and attachment protein cooperation, and prevention of receptor binding. Targeting 
the conformational change the fusion protein undergoes to drive fusion has primarily 
focused on the soluble ectodomain of the protein. The HRB domain of the Sendai virus 
fusion protein was used to develop an inhibitor of membrane fusion. The inhibitor did not 
prevent the virus from binding the target cell, but prevented membrane fusion (137). In 
addition, the heptad repeat domain of HIV gp41, respiratory syncytial virus, human 
parainfluenza virus type 3, and measles viruses were utilized to develop antiviral peptides 
that were able to block membrane fusion (138). The heptad repeat domain at the C-
terminus of three paramyxoviruses was shown to be a viable target for peptide inhibition. 
Cholesterol conjugated peptides designed to represent the heptad repeat domain of human 
parainfluenza virus 3 (hPIV3), Hendra or Nipah virus fusion protein were found to inhibit 
fusion. The tagging of cholesterol to the peptides appeared to increase the inhibitory 
activity of the peptides when compared to previous studies, which is likely the result of 
specifically targeting the peptides to the plasma membrane (139, 140). An exciting in 
vivo study with measles virus found that fusion protein heptad repeat derived peptides 
could self-assemble and, upon insertion into cell membranes, increase fusion inhibition 
potency (141). This study demonstrated that intranasal delivery of these lipid-conjugated 
peptides could inhibit infection in cotton rats. An analogous study with hPIV3 fusion 
protein heptad repeat derived peptide found that addition of cholesterol to the peptide 
increased inhibition of cell-cell fusion. This study also introduced a linker region between 
the cholesterol tag and the heptad repeat sequence; varying the linker modulated the 
levels of cell-cell fusion. An in vivo experiment with these peptides showed a significant 
decrease in viral load when cotton rats were treated subcutaneously after viral infection 
(142). Other regions of the F protein that have been targeted to prevent membrane fusion 
include the fusion peptide (143).  
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We have previously shown that the TM domains of several paramyxovirus F 
proteins associate in isolation, and, as discussed in a previous chapter, disruption of TM-
TM association resulted in a HeV F protein that triggers prematurely. Based on these 
previous studies, we hypothesized that exposing the native F protein to exogenous TM 
protein would disrupt the overall structure of the F protein: the exogenous TM protein 
would interact with the TM domain of the native F protein, ultimately disrupting the 
trimeric interaction that the F protein requires for proper folding. The structural 
disruption would lead to either pre-mature triggering or overall misfolding.  
 Studies with influenza virus, Sendai virus and measles virus have previously 
shown that the TM domain plays a role in the function of the F protein and is sequence 
dependent. Based on this premise, the TM constructs designed were homologues of the 
TM domain of HeV F. The co-expression of the TM constructs dramatically reduced F 
protein levels overall and may have reduced the initial synthesis of F (Fig 1 and 3). To 
determine whether initial synthesis was reduced, a pulse-chase with much shorter time 
points (5, 10, 15, 30 min) would need to be performed. The exogenous TM protein may 
have interacted with the F protein early in synthesis, causing a misfolding event and 
eventually degradation. On the other hand, the interaction of the exogenous TM construct 
may have caused premature triggering, which would also result in the protein being 
targeted for degradation. In the time course co-expression experiment, the F protein that 
was successfully folded in the presence of the short linker TM appeared to be properly 
cleaved. The successful cleavage event and presence on the cell surface (Fig 2 and 3) 
suggests that the exogenous TM proteins were not altering proper trafficking of the 
portion of the F protein that successfully exited the ER. From the data presented here, it is 
unclear whether the F protein was misfolded or prematurely triggered. To distinguish the 
fate of the F protein in the presence of exogenous TM protein, immuno-capture could be 
performed to determine whether the F protein is still detectable in the pre-fusion 
conformation. If the protein is misfolded, the protein may not be detected by a pre-fusion 
antibody. To determine if misfolding is occurring, co-localization studies with various 
cellular degradation markers (Rab 7, late endosomal marker; Rab11, autophagosome; 
Lamp1, lysosome; PSMA1, proteasome target) may be necessary.  
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 The specificity of the effect of exogenous TM protein was determined by co-
expressing the HeV F TM protein with PIV5 F. The co-expression of the exogenous TM 
protein did not affect PIV5 F in terms of expression or function (Fig 6), which supports 
the premise that the TM-TM interactions are specific and not simply the result of 
proximity or hydrophobicity. When considering the TM proteins for the development of 
viral therapeutics, specificity is important so that off-target drug effects can be 
minimized. The infection assay served as a proof of concept tool, demonstrating that the 
TM peptide could specifically affect viral infection. We hypothesize that the peptide 
treatment of the virus samples allowed the TM peptide to insert into the viral membrane 
and trigger or misfold the F protein. In either case, the virus is left with F protein that is 
not functional for membrane fusion. When considering the use of the TM domain as a 
potential viral inhibitor, the solubility of the peptide needs to be overcome. The 
experiments performed within utilized peptide solubilized in DMSO. In the infection 
experiment, it was apparent that the peptide tended to aggregate and may not have fully 
incorporated into the media. A recent publication demonstrated that HRB peptides 
conjugated with cholesterol were able to inhibit membrane fusion and acted as a broad 
spectrum antiviral for two paramyxoviruses (142). To maintain specificity, the TM 
peptides could be redesigned based on their target F protein TM domain, but also include 
a portion of the upstream HRB domain. The inclusion of the HRB domain may help 
overcome the solubility issue and also provide a two-fold means of preventing fusion, as 
the HRB has previously been shown to be a region important for membrane fusion (as 
discussed previously).  
Beyond viral proteins, the concept of disrupting TM-TM interactions may prove 
to be a viable therapeutic option, too. The tyrosine kinase receptor, ErbB2, was found to 
be overexpressed in high-grade inflammatory breast cancer. ErbB2 requires dimerization 
in order to trigger downstream signaling cascades that include the MAPK pathway. TM 
peptides were designed to disrupt ErbB2 TM dimerization and were found to reduce 
tumor cell growth and metastasis (92). The TM domain may serve as a viable domain for 
drug design for other tyrosine kinase receptors, as well. Another study with NRP1 
exploited the heterodimerization of NRP1 with Plexin-A1, a protein highly expressed in 
glioblastoma. A synthetic TM peptide was used to disrupt TM interactions between 
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NRP1 and Plexin-A1, resulting in reduced glioblastoma cell proliferation. The TM 
peptide was designed based on the NRP1 TM domain and diversifies the potential of 
disrupting TM-TM interactions beyond homo-oligomerization, to hetero-oligomerization 
(144).  Overall, these studies demonstrate that the TM domain may be a viable target for 
antiviral therapeutic development.   
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Figure 4.1. Linker TM construct design. Domain structure of the di-sulfide linker 
heterodimer F protein. FP, fusion peptide; HRA and HRB, heptad repeat A/B; TM, 
transmembrane domain; CT, C-terminal tail. Below the F protein is the design for 
exogenous TM constructs, containing a signal peptide, a linker composed of varying 
lengths of the HeV F HRB domain, the HeV F TM domain and CT, and an HA tag. 
Residues of the HRB domain used for the variable linker are indicated.  
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Figure 4.2. Co-expression of HeV F with TM proteins reduces total and surface 
expression. Surface biotinylation was used to analyze total (A) and surface (B) 
expression of HeV F when co-expressed with empty vector or the TM constructs. 
Expression (C) and F protein cleavage (D) are quantified using band densitometry 
(ImageQuant). *, p<0.05 student’s t-test 
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Figure 4.3. Presence of exogenous TM proteins reduces HeV F initial synthesis. A. 
HeV F was co-expressed with the short linker TM at varying ratios. As the ratio 
increases, the levels of F detected increase, as quantified in B. C. A radiolabel time 
course assay was performed when HeV F was co-expressed with the short linker TM. D. 
Band densitometry for time course.  
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Figure 4.4. Immunofluorescence shows co-localization of HeV F with the TM 
constructs. Cells were transfected with HeV F and the TM proteins and immune-labeled 
with an antibody against HeV F, 7F7, and an antibody to detect the TM proteins, anti-
HA.  
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Figure 4.5. Syncytia formation is ablated upon co-expression of the TM proteins 
with HeV F. Cells were transfected with HeV F, the attachment protein (G), and the TM 
constructs. After 24h, cells were imaged for syncytia formation, indicated by white 
arrows.  
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Figure 4.6. PIV5 F expression and fusion activity are not affected by HeV F TM 
proteins. A. PIV5 F expression levels were determined when co-expressed with the TM 
proteins by radiolabeled immunoprecipitation. Expression levels were determined by 
band density (C). B. Syncytia formation assay revealed that co-expression of TM 
constructs did not inhibit PIV5 F fusion activity. Syncytia indicated by white arrows.  
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Figure 4.7. TM peptide inhibits viral infection. A. GFP viral samples, PIV5 or HMPV, 
were treated with TM peptide designed to represent the PIV5 F TM domain, then cells 
were infected with treated virus. GFP+ cells were imaged 24hr later and counted for 
quantification (B).  
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CHAPTER 5: VIRAL FUSION PROTEIN TRANSMEMBRANE DOMAINS EXHIBIT TRIMERIC 
ASSOCIATION ACROSS SEVERAL VIRAL FAMILIES 
 
INTRODUCTION 
 
Membrane fusion is a critical event in the life cycle of an enveloped virus. Fusion 
of the viral envelope with the target cell membrane is mediated by one of the surface 
glycoproteins, the fusion protein, which studs the surface of the virus. The fusion protein 
undergoes a dramatic conformational change from its metastable pre-fusion conformation 
to the post-fusion conformation when triggered by an event such as receptor binding or a 
pH change in the surrounding environment. The change in structure is an essentially 
irreversible process, so it is important for the virus to maintain the pre-fusion structure 
until triggering is appropriate. Factors that contribute to stability of the pre-fusion state of 
the fusion protein have been identified in the ectodomain of several viral fusion proteins, 
including residues within the stalk domain. Though it is often thought to simply act as an 
anchor, the TM domain of viral fusion proteins has been implicated in protein stability 
and function as well. The influenza virus fusion protein (HA) was engineered to replace 
the TM domain with a lipid anchor, glycosylphosphatidylinositol (GPI), to elucidate the 
role of the TM domain in the fusion protein. The lipid-anchored HA protein was only 
able to promote hemi-fusion, implicating the TM domain in fusion protein function (87). 
Additional studies with Influenza virus HA have demonstrated that specific residues 
within the TM domain are important for the fusion protein oligomeric state and function 
(86, 98, 145). Trimerization of the HIV gp41 TM domain was found to enhance 
neutralizing antibody binding to the membrane proximal external region when compared 
to monomeric TM (146). Together these studies make it evident that the TM domain is of 
importance for the fusion protein, though the details require further study.  
Previously, we have shown that the HeV F TM domain self-associates in a 
monomer-trimer equilibrium, based on analysis of the SN-TM chimera in isolation via 
sedimentation equilibrium analytical ultracentrifugation (95). Since the fusion proteins of 
class I and III viral fusion proteins need to form a trimer to properly function, we 
hypothesized that it is likely that the TM domain of these fusion proteins also associates 
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in a monomer-trimer equilibrium. Additionally, essentially all of the pre-fusion crystal 
structures that have been obtained to date required the addition of a trimeric tag, 
regardless of viral family or fusion protein class, further suggesting that the TM domain 
of these proteins likely self-associates. The structure of the respiratory syncytial virus 
(RSV) fusion protein in the pre-fusion conformation was determined upon addition of a 
C-terminal fibritin trimerization domain (120). Other pre-fusion crystal structures include 
that of PIV5 F, HIV gp41, Hendra virus F, and the coronavirus spike protein, all of which 
required the addition of a coiled-coil for stabilization in the pre-fusion conformation. This 
requirement across various fusion proteins suggests that TM-TM interactions may be 
broadly relevant.  
Viral fusion proteins from four single stranded-RNA viral families were chosen to 
analyze TM-TM interactions beyond the paramyxovirus family. The viruses represent 
several major human pathogens: Ebola, influenza, severe acute respiratory syndrome 
(SARS), and rabies. The Ebola fusion protein (GP), influenza virus HA, and SARS CoV 
spike protein (S) are class I viral fusion proteins, like fusion proteins of the 
paramyxovirus family. The fusion proteins in this class undergo a dramatic structural 
rearrangement that is irreversible, so it is important to have mechanisms in place to 
maintain the pre-fusion conformation. The pre-fusion structure of the Ebola virus 
glycoprotein (GP) was determined upon binding of a human antibody, which essentially 
clamped the GP1 and GP2 subunits together, preventing triggering. The Ebola virus GP 
has two subunits that mediate attachment (GP1) and fusion (GP2) (147).  Influenza virus 
HA was the first fusion protein crystallized in its pre-fusion conformation (148). 
Influenza HA is cleaved into a disulfide linked hetero-dimer for activation (HA1, 
attachment; HA2, fusion). The pre-fusion HA structure revealed that the fusion protein 
exists as a trimer with the fusion peptide buried within the trimer interface (69). SARS 
CoV S, like Ebola and influenza fusion proteins, requires a cleavage event for activation, 
resulting in two fragments, S1 (attachment) and S2 (fusion). A recent cryo-electron 
microscopy study described several pre-fusion intermediates in which the S1 subunit was 
found on top of the S2 subunit in different “up” (active, with exposed receptor binding 
sites) or “down” (receptor-binding inactive) positions (149). The pre-fusion structure of a 
closely related coronavirus spike protein, HKU1 S, was reported recently. Similar to the 
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pre-fusion intermediates described for SARS CoV S, the attachment subunit, S1, was 
found on top of the fusion subunit, S2. This arrangement is predicted to prevent the 
fusion protein triggering until receptor binding occurs (126). Rabies GP, a class III viral 
fusion protein, is a member of the rhabdoviridae family, which includes the well-studied 
vesicular stomatitis virus (VSV). There is limited structural information about the rabies 
GP. Unlike class I viral fusion proteins, some class III viral fusion proteins are able to 
reverse the refolding process and return to the pre-fusion conformation. The selected 
fusion proteins are all trimeric and require a large conformational change to drive 
membrane fusion. Mutagenesis studies with SARS CoV S, Ebola GP, and influenza HA 
have all implicated the TM domain as important for proper folding and/or function of the 
fusion protein, however none of the crystal structures described to date include the TM 
domain (86, 87, 150, 151). With the knowledge that the TM domain of several 
paramyxovirus fusion protein TM domains oligomerize and appear to contribute to fusion 
protein function, I wanted to determine whether this property was applicable beyond 
paramyxoviruses. Utilizing the sedimentation equilibrium AUC system that has been 
established, chimeric proteins containing the fusion protein TM domain of interest fused 
with the protein staphylococcal nuclease were analyzed for oligomerization, as described 
previously.  
 
RESULTS 
 
 The TM domain of each fusion protein was predicted using the TMHMM server 
v2.0 (Table 5.1). The SN-TM chimeric proteins were expressed in E.coli and purified into 
detergent micelles at pH 7. The TM residues used for each construct were: Ebola GP, 
651-672; influenza HA, 511-536; SARS CoV S, 1193-1227; Rabies G, 429-461 (Table 
5.1). For centrifugation, the protein samples prepared in detergent micelles were density 
matched using deuterated water, to negate any contribution to sedimentation by the 
micelle itself. As a result of this preparation, any changes in sedimentation, as measured 
by absorbance, is the result of protein oligomerization.  
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TM-TM association at pH 7 
 To determine the best fit for each construct, the data points were fit to multiple 
models varying from monomer only to more complicated fits, such as monomer-trimer-
Nmer. Residual plotting, χ2 and R values were used to choose the best fit, and, when more 
than one model was applicable, the simplest model was chosen. Analysis of the Ebola GP 
and Rabies GP SN-TM constructs resulted in a monomer-Nmer fit of approximately 1:3, 
suggesting a best fit model of monomer-trimer for either. The curve fit for each at 
20,000rpm is shown with the residuals plotted above (Fig 5.1). Each analysis was 
performed at three speeds, 20, 25, and 30krpm. Although these are fusion proteins of 
different class (I and III, respectively), both exhibit the monomer-trimer equilibrium, 
supporting the overall trimeric structure of the full length fusion protein.  The SN-TM 
constructs for influenza HA and SARS CoV S were determined to best fit a monomer-
trimer-hexamer equilibrium. Again, the residual plotting and curve fitting parameters are 
shown (Fig 5.1, table 5.2). This fit adds another oligomeric species when compared to 
Ebola GP and rabies GP. The slight variation, when compared to the other class I fusion 
proteins, may be the result of association between trimers of the SN-TM constructs.  
 
TM-TM association at pH 5 
Low pH has been described as a trigger for many viral fusion proteins. The 
influenza HA protein requires exposure to low pH to initiate the fusion protein 
conformational change that drives membrane fusion. The rabies GP was found to require 
exposure to pH below 6.2 in order to drive membrane fusion. At pH 6.7, equilibrium 
occurs in which approximately half of the GP on the rabies virion are in an inactivated 
state, but fusion does not occur. These results suggest that there may be some critical 
concentration of fusion active GP that is required for membrane fusion (152, 153). It has 
been shown that the Ebola GP requires low pH; however, the low pH seems to be 
important for the activity of the cathepsins that cleave GP into its active conformation, 
not the protein conformational change (154). The SARS CoV S protein, like Ebola GP, 
requires low pH exposure for the cathepsin cleavage activity, but the acidic pH is not 
necessarily responsible for the conformational change the fusion protein undergoes (155, 
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156). To determine whether TM-TM association was affected by exposure to low pH, the 
SN-TM constructs were prepared at pH 5 and analyzed via SE-AUC. Again, the data 
points were first fit to a monomer-Nmer curve (Table 5.2), and then fit to multiple species 
curves. The SN-TM constructs for the Ebola GP, influenza HA, and SARS CoV S best fit 
to a monomer-trimer-hexamer equilibrium, as determined by residual plotting, χ2, and R 
values (Fig 5.2). Interestingly, the influenza HA SN-TM protein exhibited a monomer-
trimer equilibrium at pH 7. The rabies GP SN-TM protein, on the other hand, continued 
to exhibit a monomer-trimer equilibrium. From these results, it is apparent that the fusion 
protein TM domain various viral families self-associate, most typically as a trimer.  
 
DISCUSSION 
 
 Direct analysis of TM domains has been limited, largely as a result of the inherent 
difficulty of working with such hydrophobic domains. Sedimentation equilibrium AUC 
has provided a powerful tool for directly studying the TM domain of viral fusion 
proteins, providing further insights into the importance of this elusive domain. Other 
systems have been used to study TM domain dimerization, such as the TOXCAT system; 
however these systems are unable to characterize higher order oligomeric species. The 
data here demonstrate that trimeric TM-TM interactions occur for class I and III viral 
fusion proteins of different viral families. Class I and III viral fusion proteins are known 
to be synthesized as trimers, so it is not surprising to find that the TM domain of these 
proteins oligomerizes as a trimer. More importantly, these studies provide a tool to 
elucidate the residues that are critical for TM-TM association, and, therefore, potentially 
critical for the proper folding and function of the full length fusion protein.  
 The best fit for SARS CoV S and Ebola GP SN-TM constructs at pH 7 included 
an additional higher order species, a hexameric species. This hexameric species is likely 
the result of two sets of trimeric SN-TM interacting with one another. The Nipah virus F 
protein was recently found to oligomerize, forming higher order species up to a hexamer 
of trimers (125). The pre-fusion crystal structure of Nipah virus F protein found that six 
of the fusion protein trimers interacted in a ring structure that may contribute to pre-
fusion protein stability. The close proximity of the fusion protein in this tertiary structure 
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may provide a platform for the interaction of the trimeric TM domains. Additionally, an 
earlier study with influenza virus HA demonstrated that HA proteins located outside of 
the site of contact were also important for membrane fusion. By interfering with the HA 
outsiders, membrane fusion was inhibited, suggesting a potential role for higher order 
fusion protein oligomerization in membrane fusion (157). Interestingly, the influenza HA 
SN-TM construct fit a monomer-trimer equilibrium at pH 7 and then best fit a monomer-
trimer-hexamer equilibrium at pH 5. The addition of a higher order species at the lower 
pH may support the idea that higher order oligomerization could be important for 
membrane fusion, and that the TM-TM interactions may contribute to the 
oligomerization. In combination with the functional biochemical assays, the data obtained 
from sedimentation equilibrium AUC provides an instrument to study the contributions of 
the TM domain to fusion protein function.  
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Table 5.1. F protein TM sequence of viral F proteins from four different viral 
families. TM domain amino acid sequence of Ebola GP, Influenza HA, SARS Co-V S, 
and Rabies GP used to produce SN-TM constructs for SE-AUC.  
Fusion 
protein 
Virus family Class TM sequence 
Ebola GP Filoviridae I WIPAGIGVTGVIIAVIALFCIC 
Influenza 
HA 
Orthomyxoviridae I NEIKGVKLSSMGVYQILAIYATVAGS 
SARS  
Co-V S 
Coronaviridae I KWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLK 
Rabies GP Rhabdoviridae III HERISGVDLGLPNWGKYVLLSAGALTALMLIIF 
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Figure 5.1. Best fit curve fitting for each SN-TM construct at pH 7. Absorbance data 
and residuals were plotted for each of the four SN-TM constructs: Ebola GP, Influenza 
HA, SARS CoV S, and Rabies GP. Data shown are from the 20,000rpm spin and are 
representative of two sample preparations.  
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Figure 5.2. Best fit curve fitting for each SN-TM construct at pH 5. Absorbance data 
and residuals were plotted for each of the four SN-TM constructs: Ebola GP, Influenza 
HA, SARS CoV S, and Rabies GP. Data shown are from the 20,000rpm spin and are 
representative.  
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Table 5.2. Best fit model for each SN-TM construct. Analysis was performed at three 
different speeds and pH 5 or 7. Data are shown for the monomer-Nmer curve fit from the 
20,000rpm spin. The best fit was determined by residual plotting, χ2, and R values. 
F protein pH Monomer Nmer Best fit χ2 R 
Ebola GP 7 1 : 5.33±0.15 1:3:6 0.00304 0.999 5 1 : 5.12±0.21 1:3:6 0.00142 0.998 
Influenza HA 7 1 : 3.03±0.23 1:3 0.00449 0.999 5 1 : 5.12±0.44 1:3:6 0.00198 0.999 
SARS CoV-S 7 1 : 5.55±0.13 1:3:6 0.00851 0.999 5 1 : 4.26±0.17 1:3:6 0.00350 0.999 
Rabies GP 7 1 : 3.93±0.36 1:3 0.00480 0.998 5 1 : 3.57±0.36 1:3 0.00188 0.999 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
CHAPTER 6: DISCUSSION AND FUTURE DIRECTIONS: 
IMPORTANCE OF TM-TM INTERACTIONS AND POTENTIAL FOR THERAPEUTIC 
DEVELOPMENT 
 
 Membrane fusion is a critical process important in cellular and viral physiology. 
In cellular biology, membrane fusion is necessary for the life cycle of many proteins, 
from trafficking a newly synthesized protein to its site of action to ultimately leading to 
the degradation of that protein upon fusion of late endosomes with the lysosome. 
Membrane fusion is also important for fertilization (sperm-oocyte fusion), formation of 
muscle fibers, which requires the fusion of myoblasts to create large, multinucleated 
cells, and the formation of osteoclasts (macrophage-macrophage fusion), which is 
important for bone remodeling (158-160). Likewise, enveloped viruses rely on membrane 
fusion to initiate an infection event. Without the proper protein machinery, an enveloped 
viral particle would not be able to infect a cell and eventually propagate. With such a 
critical function, it is to be expected that the fusion machinery is finely tuned and 
regulated. After the virus has located and bound to a target cell, the fusion protein is 
responsible for mediating an incredible task: merging two lipid bilayers together. Fusion 
of two membranes requires the input of energy to overcome the kinetic barrier that is 
produced by the repulsive hydration force as the two bilayers come together. To complete 
this task, the fusion protein, initially found in a metastable conformation, undergoes 
dramatic, typically irreversible, structural rearrangements that drive membrane fusion. 
Structural data has provided some insights into the mechanism of fusion. Since 2005, 
nearly 300 structures of viral fusion proteins have been submitted to the Protein Data 
Bank (PDB). Unfortunately, these structures largely represent a few viruses, such as HIV 
env and influenza HA. More importantly, these structures are static and provided limited 
information regarding the dynamic fusion process.  
 The triggering process has been an area of interest for many viruses, as it has been 
proposed that disrupting or prematurely triggering the fusion protein is a viable 
therapeutic option. Studies of class I viral fusion proteins have largely focused on regions 
within the ectodomain as regulators of triggering. Examples include targeting the FP 
domain or the heptad repeat stalk domain of viruses, such as HIV, measles, and influenza 
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(84, 141, 161-163). Due to the difficulties of working with hydrophobic domains, few 
studies focus on the fusion protein membrane anchor, the TM domain. Additionally, the 
structural data for most fusion proteins does not include the TM domain, because of the 
complexity in crystallizing hydrophobic proteins. Despite this, all the class I and III pre-
fusion crystal structures published to date required a trimeric tag at the C-terminus of the 
protein, implicating the TM domain in pre-fusion protein stability. Mutagenic studies of 
the fusion protein TM domain suggest a functional role for the TM domain beyond 
anchoring (influenza HA, measles virus F, and Sendai virus F) (90, 98, 102, 128, 137, 
164). For example, replacement of the influenza HA TM domain with a lipid anchor, 
glycosylphosphatidylinositol (GPI), resulted in a fusion protein that could only achieve 
hemi-fusion. Interestingly, the GPI anchor only permeates one leaflet of the lipid bilayer, 
whereas the TM domain of influenza HA crosses both layers, suggesting an importance 
for TM length in membrane fusion activity (86, 87). Additionally, it was shown that there 
are length requirements for the TM domain of influenza HA. Truncations that shortened 
the TM domain from 27 amino acids to less than 17 amino acids resulted in a fusion 
protein that was only able to mediate hemi-fusion. To promote full fusion and lipid 
mixing, the TM domain may need to span the entire lipid bilayer and, for influenza HA, 
the truncation of less than 17 amino acids may not result in a TM domain that can span 
the bilayer (101). The class III viral fusion protein, VSV G, also demonstrated a length 
requirement for its TM domain. Truncation of the VSV G TM domain from 20 amino 
acids to 14 amino acids resulted in a fusion protein that could not promote syncytia 
formation. Interestingly, the TM domain truncation removed a glycine residue; 
introduction of a glycine residue in the 14 residue TM domain increased fusion activity to 
approximately 80% (165). These results suggest an important interplay between TM 
domain length and specific amino acid sequence for fusion protein function.  Here, we 
demonstrate the importance of the Hendra virus F protein TM domain in triggering and 
the potential for targeting the F protein TM domain to prevent viral entry.  
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TM-TM INTERACTIONS: CONTRIBUTIONS TO PRE-FUSION PROTEIN STABILITY 
 
 The paramyxovirus family contains many important human pathogens, including 
measles, mumps, and the zoonotic Hendra and Nipah viruses. These viruses utilize class I 
fusion proteins to fuse their lipid envelope with a target cell membrane. Therefore it is 
absolutely critical that the fusion protein only triggers when it can promote a productive 
membrane merger event. Previous work by E.C. Smith and Andreea Popa demonstrated 
that manipulation of the HeV F TM domain could alter protein trafficking and function 
(95, 99, 100). In her studies, Andreea Popa identified a leucine/isoleucine zipper (LIZ) in 
the HeV F TM domain. To build upon our understanding of TM-TM interactions, the 
LIZ, a motif known to promote protein oligomerization, was mutated for functional 
studies. By replacing the LIZ with alanine residues, the data presented here demonstrated 
that TM-TM association was dramatically reduced when analyzed in isolation by SE-
AUC. This LIZ mutant provided a great tool to study the importance of TM-TM 
association in F protein folding and function. In transient transfection experiments, the 
LIZ mutation dramatically reduced HeV F protein expression and fusion activity, as 
determined by surface biotinylation and syncytia formation assay, respectively. The 
protein that was successfully synthesized was found to trigger more readily than the wild 
type F protein when analyzed by a thermal triggering assay. These results demonstrate 
that the HeV F TM domain is not only sequence specific but contributes to pre-fusion 
protein stability. Furthermore, sequence alignment of the fusion protein TM domain of 
approximately 140 additional paramyxoviruses revealed the presence of a heptad repeat 
of β-branched residues (with the addition of Leu). This heptad repeat may be important 
for TM-TM interactions, and even pre-fusion stability, beyond the Hendra virus.  
As stated before, triggering must be spatially and temporally regulated, so pre-
fusion maintenance is critical. Because of this, it is likely that multiple motifs within the 
TM domain contribute to pre-fusion protein stability. The AxxxG motif was shown to be 
important for TM-TM interactions of HeV F via SE-AUC, though the reduction in Ka 
was approximately 5-fold for the G508A mutant, which is considerably less than the 
approximately thousand fold decrease in Ka with the LIZ mutations (95).  To determine if 
these motifs have an additive effect, the AxxxG and LIZ motifs could be mutated 
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simultaneously and analyzed for TM-TM association and functional changes. The major 
hurdle to overcome would be the reduced protein expression caused by the LIZ mutation. 
This may be addressed by synthesizing the protein in cells at a reduced temperature, to 
hopefully permit more successful folding events. Due to the dramatic changes in TM-TM 
association shown here for the LIZ mutation and previously for the AxxxG motif, it is 
likely that mutating both motifs would further decrease TM-TM association. This further 
reduction would probably deleteriously affect folding and fusion activity. In addition to 
the leucine zipper and GxxxG motif, there have been other motifs shown to be important 
for TM-TM oligomerization. For example, the presence of polar residues within the TM 
domain can promote hydrogen-bond formation and aid in oligomerization. A study with 
model transmembrane peptides demonstrated that oligomerization of the helical peptides 
was stabilized by side chain packaging of asparagine residues (166). Aromatic residues 
have been demonstrated to be important for TM-TM interactions in both model and 
physiological systems. The TM domain of SARS CoV S has an aromatic motif at the N-
terminus of the TM. Mutation of these aromatic residues, specifically the tryptophan 
residues, resulted in a fusion protein that was severely crippled in its ability to drive 
membrane fusion (150). Other motifs may also be involved in TM-TM interactions that 
have yet to be identified. Molecular dynamics studies in combination with mutagenesis 
experiments could aid in identifying additional association motifs.  
Another approach could instead enhance TM-TM interactions. When the fusion 
protein transitions from the pre-fusion to the post-fusion conformation, the stalk domain 
transitions from a coiled coil (trimer) to a six-helix bundle. From the structural data, the 
post-fusion conformation appears to place the TM domains in close proximity with the 
hydrophobic FP domains. Due to the dramatic structural rearrangements and consistence 
with the previous SE-AUC experiments, it is suggested that the TM-TM interactions are 
in equilibrium, continuously associating and dissociating with one another. If the TM-TM 
interactions were stabilized, I hypothesize that the F protein would not trigger efficiently. 
More specifically, a fusion protein with stronger TM-TM interactions would require a 
much higher heat treatment for triggering in the thermal triggering assay used previously. 
To test this, the TM domain could be mutated to include cysteine residues that could then 
be utilized to promote disulfide bonds between the TM domains. The mutations would 
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need to be made near either termini of the TM domain because disulfide bonds will not 
form when the cysteine residues are buried in the membrane. The syncytia fusion and 
thermal triggering assays could then be utilized to test the function of the disulfide linked 
mutant. By shifting the TM-TM equilibrium toward more tightly associating trimers, it is 
likely that the fusion protein would not be able to trigger and therefore could not promote 
membrane fusion. To further monitor the conformational change of the fusion protein, 
conformation specific monoclonal antibody or heptad repeat peptide binding could be 
monitored. To dissect the stage at which enhanced TM-TM association affects the fusion 
protein, a lipid mixing assay could also be used to determine fusion intermediates. Lipid 
mixing could be monitored by preparing the fusion protein in liposomes that contain 
fluorophore-conjugated lipids. The fluorescence resonance energy transfer (FRET) 
between 7-nitro-2-1,3-benzoxadizaol-4-yl (NBD) and rhodamine is utilized to monitor 
lipid mixing. Upon fusion, the local concentration of fluorophores is decreased, so 
rhodamine can no longer absorb the energy emitted from NBD, which can be detected as 
a change in fluorescence (167, 168).  When this method is modified to monitor content 
mixing, fusion intermediates can be detected.   
Class I viral fusion proteins are synthesized as homo-trimers, so it is logical to 
consider protein-protein interactions when attempting to dissect the mechanism of fusion 
protein triggering and membrane fusion. However, the fusion protein is also a type I 
integral membrane protein and, therefore, directly interacts with the lipid bilayer in which 
it is embedded. Since the lipid bilayer of a cell is a tightly packed, fluid entity, it is likely 
that the lipid content surrounding the TM domain would affect TM-TM association and, 
as a result, protein function. Upon maturation, viral particles ultimately bud from the 
plasma membrane and are enveloped in a lipid bilayer that is of similar composition to 
the plasma membrane. The plasma membrane is composed primarily of 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) with other sphingolipids 
and cholesterol present at lower concentrations. Interestingly, cholesterol has been shown 
to be important across the viral life cycle, including viral fusion, assembly and budding. 
More specifically, lipid rafts, areas of membrane that are enriched in cholesterol and 
glycosphingolipids, are utilized by many viruses to complete fusion. The membrane 
envelope of many viruses actually contains more cholesterol than the typical plasma 
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membrane from which they are taken (151, 169-172). HIV has been shown to require 
cholesterol in both the viral membrane and the target cell membrane to mediate efficient 
membrane fusion (173). The lipid rafts can increase the local concentration of the viral 
fusion protein within the viral envelope, or the cellular receptor on the plasma membrane. 
Here, we have shown that a decrease in TM-TM association resulted in a fusion protein 
that was more readily triggered than the wild type. The lipid environment surrounding the 
TM domains may also contribute to TM-TM association, especially since it has been 
shown in many cases that cholesterol is found in the viral envelope. A caveat of the SE-
AUC system used in our studies is that the SN-TM constructs are purified into lipid 
micelles, not bilayers. Though the centrifugation data provides insight into relative 
changes in TM-TM association in micelles, the TM domain naturally resides in a lipid 
bilayer, which may have additional effects on association.  Based on the general 
requirement for cholesterol in the viral envelope, I hypothesize that the lipid environment 
affects TM-TM association and therefore affects fusion protein triggering. To test this 
hypothesis, the fusion protein would need to be expressed in a lipid bilayer system, such 
as Nanodiscs or solid supported lipid bilayers, and analyzed to determine fusion protein 
triggering. These in vitro experiments would allow for the manipulation of lipid content, 
such as decreasing cholesterol content or changing lipid distribution across the bilayer 
leaflets. For example, increasing the ratio of PE to PC in the lipid bilayer may result in an 
environment in which the fusion protein is more easily triggered. The cone shape of the 
PE lipid would enhance lipid disorder, which could result in a reduction in TM-TM 
association. Viral like particles could also be used to test the effect of varying lipid 
conditions on not only fusion protein triggering, but also particle budding. Depletion of 
cholesterol in the plasma membrane would likely result in reduced production of viral 
like particles, as it has been shown that budding typically occurs at lipid rafts.  
Returning to the classic influenza HA TM example, replacement of the TM 
domain of HA with a GPI lipid anchor resulted in a fusion protein that was only able to 
mediate hemi-fusion. GPI resides in the outer layer of the lipid bilayer and only permitted 
lipid mixing, suggesting an importance for TM length in membrane fusion (86, 87). 
Interestingly, the addition of chlorpromazine was able to rescue full membrane fusion 
with the GPI anchored HA protein. Chlorpromazine typically resides in the inner bilayer 
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of the leaflet and has a destabilizing effect. On the other hand, methochlorpromazine, 
which partitions to the outer leaflet, could not rescue membrane fusion (98). These results 
suggest that the TM domain must span the lipid bilayer and destabilize the lipid bilayer 
for efficient membrane fusion. Further supporting the idea that the TM domain is 
important for membrane fusion, isolated peptides derived from different viral fusion 
protein TM domains have been shown to promote fusion in model systems alone (174). 
Though there are limited studies regarding the direct interactions between the TM 
domains of viral fusion proteins and lipids, these studies suggest that the combination of 
the TM domain and particular lipid environments results in destabilization of the bilayer, 
which permits fusion (175). In the process of membrane fusion, a dimpling of the viral 
envelope, as well as the cell membrane, must occur to initiate the formation of the hemi-
fusion stalk. Insertion of the FP into the target cell membrane is thought to initiate the 
dimpling of the cell membrane (176). The perturbation of the cellular membrane is 
probably enhanced by the presence of multiple fusion proteins inserting their FP into a 
localized area of the membrane. In the native virion, there has been no evidence of 
dimpling of the envelope prior to membrane fusion; however it is necessary for 
successful fusion. It is possible that the triggering event and insertion of the FP into the 
cell membrane results in a change in TM structure that aids in the dimpling of the viral 
membrane. Interestingly, almost all of the changes described here occur after particle 
binding, so the change in lipid environment or the TM domain specifically affects 
membrane fusion and not receptor binding. 
 
DISRUPTING TM-TM INTERACTIONS: POTENTIAL FOR A NOVEL DRUGGABLE TARGET 
 
 In order to fully exploit the fusion protein TM domain, I proposed to target TM-
TM association to prevent membrane fusion and potentially infection. Considering the 
propensity for TM-TM association and the contribution to pre-fusion stability described 
previously, it seemed plausible that TM protein derived from the fusion protein could be 
used to disrupt TM-TM association, thereby disrupting fusion protein function. I 
hypothesized that the exogenous TM protein would interact with one of the TM domains 
of the fusion protein trimer. This interaction would essentially displace a TM domain of 
87 
 
the native fusion protein and result in premature protein triggering or misfolding (Fig 
6.1). The data presented here demonstrated that exogenous TM protein could be co-
expressed with Hendra F and specifically reduced protein expression and membrane 
fusion. Furthermore, virus treated with TM peptide derived from the viral fusion protein 
exhibited reduced infectivity. Like the transient transfection experiments, the TM peptide 
seemed to be specific in its interaction: the PIV5 F TM peptide did not significantly 
reduce HMPV infection. These results shine light on an additional role for the fusion 
protein TM domain as a druggable antiviral target. The proof of concept experiments 
presented here provide the starting foundation for potential drug candidates, although 
there are several stipulations to be overcome.  
 Within the past decade, peptides have been increasingly studied in applications 
for biotechnology and therapeutic design. As of 2015, there were at least 60 US Food and 
Drug Administration (FDA) approved peptide medicines on the market. Peptide medicine 
has several strengths and weaknesses. Peptides can be highly selective and potent, 
however they may be physically unstable, prone to aggregation, and have a short half-
life. Efforts have been made to address many of these weaknesses, such as expanding 
plasma half-life by identifying and removing enzymatic cleavage sites from the peptide. 
Regardless of some of the potential shortcomings, there have been several successful 
peptide medicines developed. The most well-known anti-viral peptide is the first FDA 
approved HIV entry inhibitor, T20 (enfuvirtide). Enfuvirtide, first approved in 2003, 
targets the fusion step of HIV infection and binds the transmembrane subunit, gp41 
(177). More specifically, the peptide was derived from the amino acid sequence of the 
heptad repeat domain upstream of the TM domain. Ultimately, binding of enfuvirtide 
prevents the formation of the six helix bundle that is required to complete membrane 
fusion. Unfortunately, enfuvirtide requires twice daily injections because it is rapidly 
degraded and patients often suffer from injection site reactions (approximately 98% of 
subcutaneous injections) (178). Resistance to enfuvirtide has also been reported as a 
result of mutations in the heptad repeat motif of gp41, with only single or double point 
mutations resulting in high-level resistance (179). Despite these shortcomings, 
enfuvirtide and other peptide drugs represent an incredible step forward in drug design: 
rationally designed small molecules.  
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In recent years, these concepts have also been applied to hydrophobic targets.  
Despite the known difficulties of working with a highly hydrophobic TM domain, there 
are several examples where the TM domain of an integral membrane protein has been 
targeted to disrupt protein function. The TM domain of several receptor tyrosine kinases 
(RTK) have been studied and found to require oligomerization for downstream signaling. 
Neuropilin-1 (NRP1) and its signaling partner, Plexin-A1, dimerize to regulate cell 
migration and proliferation. Previously, Plexin-A1 was identified as a marker for 
glioblastoma. A study found that oligomerization of NRP1 and Plexin-A1 could be 
inhibited by introducing a TM peptide derived from the Plexin-A1, reducing glioblastoma 
cell proliferation (144). Not only does this study highlight the importance of the TM 
domain in receptor signaling, but it demonstrates the potential for the TM domain as a 
therapeutic target. A similar study with the tyrosine kinase receptor, ErbB, found that the 
TM oligomerization of ErbB-2 and ErbB-3 could be disrupted with a TM peptide 
homologous to the TM domain of ErB-2. These TM studies targeted integral membrane 
protein TM oligomerization, a concept that is applicable to many receptor signaling 
cascades, further broadening the potential applications of TM peptides as drug targets.  
The data I presented here further demonstrates the potential of TM peptide drugs. 
When PIV5 was treated with TM peptide derived from PIV5 F, infection was reduced. I 
proposed that the TM peptide was able to insert into the viral membrane, wherein the TM 
peptide could then interact with the TM domain of the native fusion protein. The 
interaction of the TM peptide with the fusion protein may result in premature triggering 
or misfolding, therefore preventing membrane fusion and infection. As described earlier, 
peptides have their shortcomings in drug development, especially when there are 
hydrophobic residues present. In the infection experiments I performed, a large portion of 
the peptide aggregated and, as a result, was unlikely to integrate into the virions. The 
aggregation of peptide would need to be overcome for development of TM peptides as 
drugs. To aid in solubilization, the TM domain could be modified to include part of the 
upstream heptad repeat domain. This addition could provide a two-fold effect: the heptad 
repeat residues would increase solubility and it has been shown previously that the heptad 
repeat alone can be successfully targeted to prevent membrane fusion. Recent studies 
have started to build upon heptad repeat domain inhibitors by conjugating the peptide to 
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PEG or cholesterol. This conjugation with cholesterol targets the peptide to the 
membrane, further enabling the peptide to interact with the fusion protein. PEG, on the 
other hand, is used to aid in peptide solubility. Specifically, a group conjugated PEG to 
enfuvirtide and found that the conjugation increased half-life in a rat model when 
compared to the enfuvirtide alone (180). The heptad repeat domain upstream of the TM 
domain is a common target to prevent membrane fusion. Another study found that 
conjugating a heptad repeat peptide derived from HPIV3 with cholesterol enhanced 
antiviral potency (141). By instead adding a portion or the full length TM domain, the 
fusion protein could then be disrupted in two domains, further increasing the possibility 
of disrupting its function. Together, the data presented here further supports the potential 
of fusion protein TM-TM oligomerization as a target for preventing membrane fusion.  
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Figure 6.1. Model for TM peptide interaction with fusion protein. 
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